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Abstract
Introduction: Pulmonary air leaks from unhealed lung tissue are one of the most
common complications after lung surgery. This adverse event leads to a delay in
chest tube removal, prolonged pain, increased infections, prolonged hospital
stay, and increased costs to the health care system. Objective: To define the
most appropriate safe dose of dextrose 50% (D50) to seal air leaks in patients
that have undergone lung resection surgery. Primary outcome was the
occurrence of any adverse event. Methods: Prospective, single-arm, singlecenter, rule-based escalation traditional 3+3 design phase I trial where patients
with an active air leak on postoperative day #2 received intrapleural D50 at
various dosage. Results: 12 patients were recruited. Increments of 50 mL, 100
mL, 150 mL and 200 mL were tested. There was no severe adverse event. Air
leak volume significantly decreased in the 24 hours following D50 administration
compared to before (221 vs 31 L, p=0.013). Chest tube output remained similar
(282 vs 365 mL, p=0.198). Transient non-significant increase of the glycemia was
noted 1 hours after D50 (7.4 vs 10.0 mmol/L, p=0.156). 33% (4/12) were
discharged home with a one-way valve. Pain level was not impacted by D50.
Conclusion: Hypertonic intrapleural glucose to treat air leaks after lung resection
appears safe. The optimum dose is 150 mL. Its efficacy is promising and needs
to be further studied prospectively.
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Summary for Lay Audience

Lung resection surgery is frequently performed to remove lung cancer.
Lung tissue is cut, and a drainage tube is left beside the lung at completion of the
surgery to remove fluid that could accumulate around the lung. Air may also be
leaking out of the lung, preventing the tube from being removed as the lung
would collapse. Air leaks are also associated to infections around the lung, and
the longer the leakage persists, the higher the risk of infections. Air leaks prolong
length of hospital stay, and therefore once a leak occurs efforts are made to seal
it as soon as possible.
Several ways exist to stop those air leaks, including injecting a product in
the chest through the existing tube to create inflammation around the lung. This
process called pleurodesis has been performed using various agents, including
talc. High concentration glucose (sugar) has emerged from reports as being a
promising agent to achieve the same purpose, with less toxicity.
Before larger scale studies are performed, we aimed at assessing the
safety of various dose of high concentration sugar. We enrolled 12 patients. No
major side effects were linked to the injection of sugar in the chest. The air leak
rate decreased dramatically. The pain level and fluid drainage did not change.
The blood sugar temporarily rose without any meaningful consequence.
Using this data, we can design a larger scale trial where we measure how
effective sugar is compared to placebo in sealing those air leaks after lung
resection surgery.
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CHAPTER 1

1

INTRODUCTION

1.1

BACKGROUND AND OVERVIEW

Air leaks from unhealed lung tissue are one of the most common complications
following lung surgery including wedge resection, segmentectomy and
lobectomy. Air leaks can lead to a delay in chest tube removal, prolonged pain,
increased infections, prolonged hospital stay, and increased costs to the health
care system1. Different agents have been used to seal air leaks by creating a
pleurodesis (adhesions to obliterate the pleural space between the visceral and
parietal pleura). They range from minerals (talc, our current standard) to cytotoxic
agents (bleomycin). The success with each of these agents has been variable
and come with the cost of complications that have restricted their use during the
post-operative period 2. Cross-contamination of talc with asbestos has been
described in the past3 5, and although medical-grade talc is consider safe, some
patients express concerns with its use in clinical practice. There has been recent
interest in the use of 50% hypertonic glucose (D50) to create pleurodesis, with
encouraging reports coming mostly from Asia 6 8. We have performed a pilot
study using 180 mL of D50 instilled through the chest tube for the management
of post lobectomy air leak with encouraging results 9, leading to reduced duration
of air leak, chest drainage and hospital stay when compared to an historical
cohort. This preliminary study used strict inclusion criteria of only lobectomy
patients and excluded many other patients, such as patients with diabetes or any
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postoperative hyperglycemia that may benefit from this intervention. Also, the
optimal dose of D50 was determined empirically and never clearly defined by
previous work. It has been reported that high doses of D50 was associated to
acute lung injury in some reports 10. It is therefore critical that the optimal safe
dose is clarified.

The objective of this work was to define the most appropriate safe dose of D50 to
heal air leaks in patients that have undergone lung resection surgery (Phase I
study).

We hypothesized that in patients with a post-operative air leak following lung
resection, the bedside administration of D50 into the pleural space on postoperative day 2 was safe (Phase I trial). This will provide the basis and data to
proceed with a formal Phase II study to assess the effectiveness of the chosen
dosage in reducing the duration of chest tube drainage, and then a Phase III
randomized clinical trial against talc.

We anticipate that D50 will replace talc as our pleurodesis agent of choice and
become the new standard not only for sealing air leaks following lung resection
surgery, but also to achieve pleurodesis for chronic pleural effusions. Should we
be successful in reducing post-operative air leaks in patients undergoing lung
resections, we will reduce their hospital length of stay. This intervention should
improve patient outcomes by shortening the duration that a chest tube is required

3

in the pleural space, reducing post chest tube removal pneumothoraces,
decrease chest tube related pain, decrease the risk of post-operative infections,
hospital length of stay, and health care costs. Should this simple, inexpensive,
and novel therapy work to heal pulmonary air leaks, it will be a significant
oracic
Surgery.

In this thesis, dextrose 50%, glucose 50%, hypertonic glucose, hypertonic
dextrose, and D50 are used interchangeably.

4

CHAPTER 2
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2

LITERATURE REVIEW

2.1

AIR LEAK AFTER LUNG SURGERY

Leakage of air after lung surgery is frequent. Lung surgery is performed for
various indications. Resection of lung parenchyma for benign or malignant
disease is routinely performed in tertiary health care institutions. Leakage of air
after lung resection is one of the most frequent adverse events and is the most
common cause of prolonged length of stay 11. Data extracted from the European
Society of Thoracic Surgeons database reported a rate of prolonged air leak
(more than 5 days) of 9.9% 12 after lobectomies or pneumonectomies. The
Society of Thoracic Surgeon General Thoracic Surgery database reports a
similar rate of prolonged air leak of 10.4% 13 after lung resection. In a series of
319 patients, Okereke and al.1 quantified that the prevalence of air leak after
anatomic lobectomies was 58% immediately at the end of the surgery in the postanesthesia recovering unit. The median air leak duration was 3 days, but up to
10% of patients were still leaking 7 days later. Our own experience during a
randomized controlled trial 14 evaluated the role of autologous platelet rich plasma
and concentrated platelet poor plasma on reducing air leak after lobectomies for
cancer documented a 43.3% air leak prevalence at 4 days in the control group. A
recent a
institutional database showed that out of 866 patients who underwent a minimally
invasive wedge or lobectomy from July 2012 to June 2017, at least 102 patients
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(11.8%) suffered from a prolonged air leak (five days or more). Incidence of postoperative air leak has been observed up to 15-26% in other single institution
large series15,16. As the occurrence of adverse events of any grade leads to
prolonged length of stay after lung cancer resection 17, and that prolonged air
leaks are directly associated to pulmonary complications (including empyema),
readmissions and delayed hospital discharge 18, it is important to find strategies to
mitigate the impact of such adverse events.

2.2

PERSISTENT AIR LEAK IN THE SETTING OF SPONTANEOUS
PNEUMOTHORAX

Air leaks not only arise post-operatively, but they can also occur spontaneously,
giving rise to a pneumothorax. Pleurodesis and resolution of the leak are desired,
similar to patients with post-operative air leaks. Treatment usually includes
simple drainage of the accumulated air via tube thoracostomy 19 as recommended
in the 2010 Guidelines of the British Thoracic Society. The annual incidence rate
of primary and secondary spontaneous pneumothoraces is reported to be 22.7
cases/100 000 people 20 in an analysis of the France national database from 2008
to 2011, with a subset that may require additional treatment than just simple
drainage. The American College of Chest Physicians guidelines on spontaneous
pneumothoraces published in 2001 21 recommended that patients with persistent
air leaks (more than 4 days) should be evaluated for surgery to address the leak,
followed by pleurodesis to reduce the recurrence rate. This is concordant with the

7

British Thoracic Society 2010 guidelines 19. Surgical treatment typically consists
on finding the area of lung parenchyma leaking air and surgically remove it by
stapling across normal lung tissue, in addition of performing a procedure that will
promote pleurodesis post-operatively19,22. For non-operative candidates 23,
chemical pleurodesis can be attempted. Other methods include keeping the tube
with a one-way valve for a prolonged time hoping the leak will eventually stop
and the use of endobronchial devices or drugs. Methods applied to promote
pleurodesis in the post-operative setting should also be effective in this
population.

2.3

MONITORING OF AIR LEAK

Lung resection almost always requires one or more drainage tube(s) left in the
pleural cavity to collect the excess of fluid and air that could accumulate around
the lung. Such accumulation can lead to catastrophic physiological
consequences for the patient, culminating to cardiorespiratory arrest if a tension
pneumothorax develops or if bleeding is unrecognized for instance. This tube
needs to be connected to a chest drainage system to monitor the amount and
quantity of fluid, and also to prevent reflux of air from the outside world back into
the chest as the pleural cavity is a negative pressure environment compared to
the atmospheric pressure.
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Chest drainage systems can be classified as either analog or digital. Analog
drainage systems are modifications of the three-bottle chest drainage system 24.
They rely on the visual evaluation of the presence of air bubbles in the water
chamber by an observer who then reports it in the patient chart typically using a
standardized classification 22,25

27.

These systems are relatively inexpensive but

are cumbersome for patients as the device is relatively large, and subjective. In
addition, if suction is required, the analog device has to be connected to the

systems, digital pleural drainage systems are a newer technology that have been
shown to improve interobserver reliability in the assessment of pulmonary air
leak28, as the objectivity is increased. Additional advantage by design includes
recording of the air leak over time and better ambulation for patient as the suction
is battery powered. Gilbert performed a randomized controlled trial 29 of digital
versus analog pleural drainage systems after lung resection in which the digital
system reduced the number of chest tube clamping trials. Using specific air leak
flow thresholds for chest tube removal on the digital system, no patients had
chest tube reinsertion for worsening pneumothorax or subcutaneous
emphysema. These digital devices are being incorporated more and more
included in post-operative clinical pathways30. A recent meta-analysis including
10 randomized controlled trials enrolling 1268 patients showed that digital
systems statistically reduced the duration of chest tube placement, the length of
hospital stay, the air leak duration, and postoperative costs 31. They are now

9

2.4

PLEURODESIS

2.4.1 DEFINITIONS AND INDICATIONS

Pleurodesis is defined by Hallifax et al. as the permanent apposition of the
32.

Inflammation within the

pleural cavity is voluntarily created to generate adhesions and pleural symphysis.
It is categorized as chemical when the mechanism involves the administration of
an agent within the pleural space, or surgical when the parietal pleura is
surgically excised (pleurectomy) or damaged (pleural abrasion). The aim in both
cases is to prevent future collapse of the lung caused by either air or fluid.

Several indications exist to perform pleurodesis. Prevention of recurrent
spontaneous pneumothoraces and treatment of an active air leak in non-surgical
candidates are the main indications 32. Malignant pleural effusions may also be
treated by chemical pleurodesis 33. Benign effusion such as chylothorax have also
been treated by performing chemical pleurodesis 34

36.

2.4.2 AGENTS USED TO ACHIEVE CHEMICAL PLEURODESIS

All the sclerosing agents possess the same attribute: damaging pleural
mesothelial cells to trigger an inflammatory cascade where a neutrophilic
exudate is formed. Multiple factors come at play including the ability of fibroblasts
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and mesothelial cells to produce collagen, and an equilibrium between
metalloproteinases and plasminogen activators37. Certain anti-inflammatory
agents such as steroids and diclofenac reduce the degree of pleurodesis in
experimental studies38,39, while others (cyclooxygenase-2 inhibitors) do not 37.

Several agents exist. In a recent systematic review 32 assessing the effectiveness
of chemical pleurodesis in spontaneous pneumothoraces recurrence prevention
and in a Cochrane meta-analysis33 on interventions for the management of
malignant pleural effusions, the following agents were listed to induce
pleurodesis:
Talc (mineral, most used agent)
Tetracycline (antibiotic)
blood
minocycline (antibiotic)
iodopovidone (antiseptic agent)
silver nitrate (antiseptic agent)
quinacrine (derivative of anti-malarial drug)
fibrin glue
bleomycin (chemotherapy agent)
Cryptosporidium parvum (bacteria)
Interferon (immunomodulating agent)
Mustine (chemotherapy agent)
mitoxantrone (chemotherapy agent)
11

mepacrine (anti-malarial drug)
doxycycline (antibiotic)
triethylenethiophosphoramide (chemotherapy agent)
Adriamycin (chemotherapy agent)
Viscum (parasitic plant)
OK-432 (inactivated preparation of Streptococcus pyogenes, very popular
in Japan6)

They all have various risk of toxicity, and a simpler agent such as dextrose could
possibly provide similar efficacy with a better safety profile. For example, C.
parvum and mepacrine are known to induce fever more frequently than other
agents. Blood may be difficult to collect and inject, and may clog the chest tube.
Mepacrine, mitoxantrone and C. parvum are associated with pain33. Patients may
be allergic to some of these agents.

While not listed in the above-mentioned reviews, administration of hypertonic
glucose in the pleural cavity has been described to obtain pleurodesis (cf below),
and its first documented use to as a chemical pleurodesis agent was in 1906 by
Spengler40, and first success in 192341,42.

2.5

HYPERTONIC GLUCOSE TO ACHIEVE PLEURODESIS
OF ALL DATA AND SYSTEMATIC REVIEW

12

SUMMARY

The systematic review was conducted in accordance to the Preferred Reporting
Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines 43 (Table
1). The search was completed on December 9, 2019 and updated on January 3,
2020. The search strategy is located in Appendix M.

Articles where the intervention was intrapleural administration of any volume of
hypertonic glucose (Intervention) on human patients (Population) were included.
The objective of the search was to find data on the safety (Outcome) of
intrapleural hypertonic glucose to induce pleurodesis. It was mandatory for the
article to include the population size, and information on adverse events.
Exclusion criteria consisted of non-human or pediatric populations, non-English
abstracts and/or articles and review articles.

Two authors (M Qiabi, A Ednie) extracted the data from the eligible studies and
cross-checked the results subsequently. There was 100% agreement in the
results. Variables that were extracted included: general study characteristics
(author, year, study design, location, number of patients), patient population,
intervention and occurrence of adverse events.

A total of 98 entries were found after performing the PubMed search. After

articles6

8,10,34,35,44 50

were kept for the review.
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title, abstract, and sometimes the article itself, one9 additional article was added
to the review.

SCOPUS search yielded 7 results, none of which were either relevant or new
addition compared to the other two databases.

Cochrane search yielded 9 results, none of which were either relevant or new
addition compared to the other three databases.

Finally, Web of Science search yielded 88 results, three 36,51,52 of which were new
additions compared to the other four databases.

After reading each article and reviewing the references, 6 42,53

57

additional

articles have been added to the list. A total of 23 articles were therefore
reviewed, covering 447 patients (Table 1). The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (Figure 1) and
the PRISMA Checklist (Table 2) are attached. The volume of intrapleural
dextrose during initial administration ranged from 30 mL to 500 mL. The maximal
total volume administered was 1500 mL (3 times 500 mL over 3 days).

14

2.5.1 INDICATIONS

Administration of hypertonic glucose into the pleural cavity was performed for the
following indications:
spontaneous pneumothorax (17 studies 6

8,10,42,44 50,53,54,56,57,

313 patients)

prolonged air leak after lung resection (5 studies6,9,52,54,55, 70 patients)
chylothorax (3 studies 34

36

, 42 patients)

malignant pleural effusion (2 studies 51,54, 22 patients)

2.5.2 KNOWN POTENTIAL RISKS

In five papers6,9,52,54,55, the population studied were post-lung resection patients
with air leak (70 patients). In these 70 subjects, reported adverse events were as
follow:
mild transient hyperglycemia (n=26/70)
mild transient chest pain
mild transient fever
mild increase in chest tube output

In these 70 patients, reported adverse events were mild. This population is
similar to the population we plan to study. The concentration of dextrose was
50%. Except for one study 55 in which the data was not available, they all had
administration of 200 mL, repeated up to 2 other times for a total of 600 mL over

15

3 days. There was no infectious complication in this population with air leak after
lung resection.

In the whole population (447 patients) comprising all indications for pleurodesis,
infectious complications related to the intervention were rare. One study 7 where
20 patients had spontaneous pneumothoraces and were treated with bullectomy,
mechanical abrasion and administration of 500 mL of Dextrose 50% in the
operating room

8

where 13 patients had spontaneous pneumothorax treated with a chest tube and
then administration of between 200 to 500 mL of dextrose 50%, repeated up to a
total of 3 times (500 mL administered 3 times over 3 days) reported 2 patients

prolonged period of time (25 and 35 days), and they both had repeated
administration of 500 mL of dextrose 50% (one had a total of 2 doses and the
other 3 doses). All these 3 patients were treated conservatively with antibiotics.

Ischemic colitis induced by dehydration was reported after the administration of
400 mL of Dextrose 50% on a 97 years old patient to induce pleurodesis after a
spontaneous pneumothorax 53. This was treated conservatively with rehydration
and surgery was not required.

16

Chee44 reported a case of dextrose pneumonitis. The 51 years old male with
chronic obstructive airways disease complicated by cor pulmonale and
hypercapnic respiratory failure had a spontaneous pneumothorax. He had a
prolonged air leak for 41 days. Intrapleural instillation of 50 mL of Dextrose 50%
was performed and the patient experienced cardiorespiratory collapse requiring
cardiopulmonary resuscitation. It was noted that a copious quantity of secretions
was coming from the endotracheal tube, positive for glucose by a dipstick. The
patient recovered well after that event and the leak stopped. It was postulated
that osmotic pulmonary edema may have been caused by the high tonicity of the
dextrose 50%.

Of the 447 patients who underwent intrapleural hypertonic dextrose
administration for pleurodesis, a total of 3 deaths were reported.

1- In Tsukioka7 paper, a 79 years old male with severe emphysema,
unresectable lung cancer who recently had chemotherapy, underwent a
bullectomy, mechanical abrasion of the pleura, and administration of 500
mL of dextrose 50% in the pleural cavity. Twenty-four days after his
surgery, he passed away from a pneumonia. It is unclear whether his
death is related to the administration of a sclerosing agent.

2- In Hamada10 paper, a 72 years old male with a stage IV lung cancer and
severe emphysema, presented with spontaneous pneumothorax. He was
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first treated with 5 rounds of OK-432 (sclerosing agent available in Japan
to induce pleurodesis), but it did not work, and the leak was still present.
Then, 4 rounds of autologous blood and 200 mg of minocycline were
injected into the pleural cavity via the chest tube, again without success.
Finally, 200 mL of dextrose 50% was injected into the pleural space. The
patient suffered from acute respiratory distress syndrome and had to be
intubated. He eventually died from progression of respiratory failure. While
there seems to be a temporal association, the causality is uncertain.

3- In Hamada10 paper, a 84 years old male with idiopathic pulmonary fibrosis,
on home oxygen and hypercapnic respiratory failure developed a
spontaneous pneumothorax. A chest tube was inserted, and 400 mL of
dextrose 50% administered into the pleural space. Immediate pain and
respiratory failure occurred. It was recommended for the patient to be
intubated, but the family refused. The patient died 1 week later from
progression of respiratory failure.

In the case of Patient 1, the death seems to be related to a nosocomial
pneumonia and not from the intervention. Patient 2 had multiple attempts at
pleurodesis with various agents (OK-432, blood, minocycline) before dextrose
was tried. This is not the type of intervention planned in the current proposed
study. Patient 3 seemed to have an acute reaction to dextrose 50%. The volume
administered is twice the maximum dose we are planning to use.
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In summary, after reviewing the current literature, the most common and
potential safety concerns our study group is ready to face are:
acute respiratory distress
dehydration
pain
hyperglycemia
fever

It is hypothesized that the value of the information gained by performing this
study will allow health care providers to have another option when comes the
time to offer a patient chemical pleurodesis (instead of offering talc), thoracic
surgeons or respirologists will have the option of administering hypertonic
glucose. Talc is associated to acute toxicities like the Acute Respiratory Distress
Syndrome58, and healthcare workers with occupational exposure to talc may be
at higher risk of developing lung cancer 59. Of note, the risk of reporting bias
exists, as papers with severe adverse events may not have been published. On
an individual study level, most of these studies were retrospective, with all the
biases associated with this design (selection).

2.5.3 KNOWN POTENTIAL BENEFITS
After pulmonary resection, air leak is one of the most common complications
arising from lung parenchyma at sites of division of adhesions, fissure dissection
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or lung retraction for exposure. A chest tube inserted at the end of the procedure
will drain any ongoing air-leak allowing the underlying lung to re-expand.
Patients who have an air leak on post-operative day 2 typically are offered
observation, hoping the air leak will seal by itself. However, previous work
showed that a significant number of patients who still leak on POD2 will have a
prolonged air leak (more than 5 days), and then will be typically offered one of 3
options:
1- waiting a longer period of time before removing the chest tube, with possibly
discharging the patient home with a small one-way valve if the lung stays well
inflated, hoping the leak will have stopped at the next outpatient visit
2- injection of a sclerosing agent (such as talc) into the pleural space hoping the
leak will stop
3- reoperation, hoping to stop the leak
It is known in the thoracic surgery literature that the longer a leak persists, the
more likely the patient may suffer from an infection of the pleural space
(empyema)60,61. Other complications such as catheter-related discomfort,
arrhythmia or deep vein thrombosis could potentially be attributed to prolonged
length of stay.
Most reports from Table 1 have shown some efficacy in inducing pleurodesis and
achieving the desired outcome. We postulate that participants to the study will
therefore potentially be able to be discharged home sooner, have their chest tube
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removed sooner (leading to pain relief), and because the leak would stop earlier,
there is a hypothetic benefit in reducing the risk of post-operative infectious
complications18.
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Author

Year

Chen34

2010 Retrospective
case series
2008 Prospective
cohort

China

Tsukioka7

2013 Retrospective
cohort

Japan

Hamada10

2017 Retrospective
case series
2002 cohort

Japan

Chung49

Peng50
Chee44

Study design

Location

n

Population

5 post-esophagectomy chylothorax

South Korea 49 primary spontaneous pneumothorax

China

20 secondary spontaneous pneumothorax

2 spontaneous pneumothorax
45 recurrent pneumothorax

Adverse events

50% glucose + 0.1% lidocaine (volume?) through
the tube
thoracoscopic procedure (bleb
resection/bullectomy/electrocoagulation) +
instillation of dextrose 20% 200 cc
VATS bullectomy + mechanical abrasion +
dextrose 50% (500 cc)

self-resolving dyspnea

1- 200 mL of dextrose 50%
2- 400 mL of dextrose 50%
60-80 mL of Dextrose 50% through the tube

2 deathsb

50 mL dextrose 50%

pulmonary edemac

200 mL of 50% glucose, between 1 and 3 doses,
7 patients had OK-432 after their 3rd dose for
failure of the glucose to work
50% glucose, 400 mL

mild transient hyperglycemia in 20/46 patients

rate of fever 22% (dextrose group) vs 10% (no
dextrose group)
1 deatha 24 days after the surgery from a
pneumonia,1 prolonged air leak (15 days), 2

7/45 had mild pain

1992 Retrospective
case report
2016 Retrospective
cohort

Singapore

Takanashi53

2015 Retrospective
case report

Japan

Togo54

2016 Retrospective
cohort
2013 Retrospective
cohort

Japan
Japan

29 14 pneumothorax, 11 post-lung resection
air leak, 4 malignant pleural effusion
13 spontaneous pneumothorax

Canada

10 post-lobectomy air leak

Frick45

2016 Prospective
cohort
1990 Cohort

Germany

32 spontaneous pneumothorax

Sumitomo52

2017 Cohort

Japan

13 post-lung resection air leak

Kitagata55

2018 case report

Japan

1 Air leak post right lower lobectomy

2016 case report

Japan

pleurodesis with glucose 50% and minocycline

none

Kajikawa57

2017 case series

Japan

1 spontaneous pneumothorax on
mechanical ventilation
5 spontaneous pneumothorax

pleurodesis with 200 mL glucose 50%

transient hyperglycemia

Hennell42

1939 case report

US

2 Chronic pneumothorax

glucose 50% 50 mL, then 60% 67 mL

none

Fujino6

Tsukioka8

Albargawi9

Yaginuma

56

Japan

1 spontaneous pneumothorax

Intervention

46 35 post-lung resection patients with air
leak and 11 patients with pneumothorax
and prolonged air leak with a tube in place
1 spontaneous pneumothorax

ischemic colitis secondary to severe
dehydratation (1960 mL/4 hours), prerenal acute
renal failure
200 mL of 50% glucose (2 patients had 100 mL
Mild transient hyperglycemia, chest pain and
for « poor performance status »)
fever
200 - 500 mL 50% glucose through the tube, they 2 "bacterial pleuritis" (both of them required more
often required more than one treatment
than 1 treatment, and they had their tube 25 and
35 days, treated with antibiotics only), 1 aspiration
pneumonia
200 mL dextrose 50% with lidocaine, once or
mild increase in chest tube output, mild increase
twice
in blood sugar
thoracoscopic pleurodesis with electrocoagulation Horner syndrome (secondary to pleural
of bullae, visceral/parietal pleurae cauterized,
cauterization)
chemical pleurodesis with dextrose 50%
200 mL glucose 50%, repeated as needed (2
none
patients had pleurodesis twice)
glucose 50%
none

Table 1 - List of all studies. VATS: video-assisted thoracic surgery, POD: post-operative day. a,b,c cf description of the events in the text
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Author
35

Year

Study design

Location

n

34 Chylothorax post-esophagectomy (30),
lobectomy (2) and mediastinal mass
resection (2)
106 Spontaneous pneumothorax

Lai

2019 Prospective
cohort

China

Tsuboshima47

2018 Retrospective
cohort

Japan

Yamane48

2014 Case report

Japan

Van den
Brande46
Li36

1989 RCT

Belgium

2011 Case series

China

Khanna51

2010 Retrospective
cohort

Great Britain

Population

1 Spontaneous pneumothorax

Intervention

Adverse events

daily 50% dextrose 100 mL (IL-2 if diabetic)

Electrolytes imbalances attributed to chyle
leak. No pleural infection

Bullectomy + 50 mL 50% glucose solution for
pleural coating on an absorbable sheet

No empyema in the glucose group, mild
increase in pain score (3 vs 2), marginal
increase in chest tube output. No
dehydratation, no long-term restrictive
physiology on pulmonary function tests
None

50% glucose

10 Spontaneous pneumothorax
3 Chylothorax post-pulmonary resection
18 Malignant pleural effusion

30 mL of 30% glucose + 250 mg of
oxytetracycline
50% glucose

None (no fever, no pleural effusion)

Talc slurry in dextrose 50% solution

None reported

None reported

Table 1 - List of all studies (continued). VATS: video-assisted thoracic surgery, POD: post-operative day. a,b,c cf description of the events in the text
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Identification

Figure 1 - PRISMA 2009 Flow Diagram

Records identified through
database searching
(n = 1177)

Additional records identified
through other sources
(n = 9)

Eligibility

Screening

Records after duplicates removed
(n = 1129)

Records screened
(n = 1129)

Full-text articles assessed
for eligibility
(n = 122)

Included

Studies included in
qualitative synthesis
(n = 23)
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Records excluded
(n = 1007)
Full-text articles excluded (n = 99)
- Wrong/no intervention (n = 80)
- Review article (n = 10)
- Missing data (n = 6)
- # unknown (n = 2)
- Duplicate population (n = 1)

Table 2 - PRISMA 2009 Checklist

# Checklist item

Reported
on page #

1

Identify the report as a systematic review, meta-analysis, or both.

12

2

Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and
implications of key findings; systematic review registration number.

12-13

Rationale

3

Describe the rationale for the review in the context of what is already known.

6-12

Objectives

4

Provide an explicit statement of questions being addressed with reference to participants, interventions,
comparisons, outcomes, and study design (PICOS).

13

Protocol and registration

5

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide
registration information including registration number.

n/a

Eligibility criteria

6

Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered,
language, publication status) used as criteria for eligibility, giving rationale.

13

Information sources

7

Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify
additional studies) in the search and date last searched.

13-14

Search

8

Present full electronic search strategy for at least one database, including any limits used, such that it could be
repeated.

13 and
Appendix M

Study selection

9

State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable,
included in the meta-analysis).

13

Section/topic
TITLE
Title

ABSTRACT
Structured summary

INTRODUCTION

METHODS

Data collection process

10

Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any
processes for obtaining and confirming data from investigators.

n/a

Data items

11

List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and
simplifications made.

n/a

Risk of bias in individual
studies

12

Describe methods used for assessing risk of bias of individual studies (including specification of whether this was
done at the study or outcome level), and how this information is to be used in any data synthesis.

n/a

Summary measures

13

State the principal summary measures (e.g., risk ratio, difference in means).

13
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Table 2 - PRISMA 2009 Checklist
Synthesis of results

Section/topic

14

Describe the methods of handling data and combining results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis.

n/a

Reported
on page #

# Checklist item

Risk of bias across studies

15

Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective
reporting within studies).

n/a

Additional analyses

16

Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done,
indicating which were pre-specified.

n/a

Study selection

17

Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions
at each stage, ideally with a flow diagram.
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Study characteristics

18

For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period)
and provide the citations.

22-23

Risk of bias within studies

19

Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).

n/a

Results of individual studies

20

For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.

22-23

Synthesis of results

21

Present results of each meta-analysis done, including confidence intervals and measures of consistency.

n/a

Risk of bias across studies

22

Present results of any assessment of risk of bias across studies (see Item 15).

n/a

Additional analysis

23

Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).

n/a

Summary of evidence

24

Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to
key groups (e.g., healthcare providers, users, and policy makers).

15-19

Limitations

25

Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of
identified research, reporting bias).

n/a

Conclusions

26

Provide a general interpretation of the results in the context of other evidence, and implications for future research.

15-19

27

Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for
the systematic review.

n/a

RESULTS

DISCUSSION

FUNDING
Funding
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3

RATIONALE, RESEARCH QUESTION, OBJECTIVE AND HYPOTHESIS

Air leaks from unhealed lung tissue are one of the most common complications
after lung surgery including wedge resection, segmentectomy and lobectomy. Air
leaks can lead to a delay in chest tube removal, prolonged pain, increased
infections, prolonged hospital stay, and increased costs to the health care
system1. Different agents have been used to heal air leaks by creating a
pleurodesis (adhesions to obliterate the pleural space between the visceral and
parietal pleura). The success with these agents has been variable and come with
the cost of complications that have restricted their use the post-operative period 2.
There has been recent interest in the use of D50 to create pleurodesis with
encouraging reports coming mostly from Asia 6 8. We have performed a pilot
study using D50 instilled through the chest tube for the management of post
lobectomy air leak with encouraging results 9. This preliminary study used strict
inclusion criteria of only lobectomy patients and excluded many other patients
such as patients with diabetes or any postoperative hyperglycemia that may
benefit from this intervention. Also, the optimal dose of D50 was chosen
empirically and never clearly defined by previous work. It has been reported that
high doses of D50 was associated to acute lung injury 10. It is therefore critical
that the optimal safe dose is clarified. A phase I study was therefore designed.
Research question: Is intrapleural dextrose 50% administered 2 days after lung
resection safe when an air leak is present?
Objective: To confirm safety of various dosage of D50 to heal air leaks in
28

patients that have undergone lung resection surgery (Phase I study).
Hypothesis: In patients with a postoperative air leak following lung resection, the
bedside administration of D50 into the pleural space on postoperative day 2 is
safe (absence of severe adverse events related to D50).
We predicted that D50 would be found safe because no severe adverse events
occurred with optimum dose (dose providing the best efficacy for the most
acceptable toxicity) found in this Phase I study. Results provide the motivation
and data to proceed with a formal Phase II study to assess the effectiveness of
the chosen dosage in reducing the duration of chest tube drainage, and then a
Phase III randomized clinical trial comparing D50 to talc.
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4

METHODS

A detailed protocol (Appendix F, protocol MQRM711 v2.05) has been submitted
to the Health Canada Therapeutic Products Directorate which issued a No
Objection Letter (Appendix E) following evaluation of our Clinical Trial Application
(CTA, control number 229051). The protocol was elaborated using the National
Institutes of Health (NIH) protocol templates for clinical trials 62. Training in Part C,
Division 5 of the Food and Drug Regulations was completed by the investigating
team as part of a Health Canada requirement for the investigation of drugs in
regulated clinical trials involving human subjects.

The protocol (Appendix F) outlines the background information and scientific
rationale, objectives and purpose, study design and endpoints, study enrollment
and withdrawal, study agent, study procedures and schedule, assessment of
safety, clinical monitoring, statistical considerations, source documents and
access to source data/documents, quality assurance and quality control,
ethics/protection of human subjects, data handling and record keeping, study
administration, conflict of interest policy, and literature references. This CTA was
requested by the Western University Health Sciences Research Ethics Board
(HSREB) after Full Board review. The study was subsequently approved by
Western University HSREB (#113906) and Lawson Health Research Institute (R20-071). The trial is registered at ClinicalTrials.gov (NCT03905408).
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This trial took place at London Health Sciences Centre (LHSC)

Victoria

Hospital, London, Ontario, on the Thoracic Surgery ward (C5-300).

Below is a summary of the protocol.

4.1

DESCRIPTION OF THE STUDY DESIGN

In this prospective single-arm, phase I, single-center trial, patients with air leak
on postoperative day 2 following lung surgery were invited to participate in the
study. The precise definition of air leak is found in section 4.5. The solution to be
used as pleurodesis agent consisted of sterile 50% glucose injected in the chest
tube, followed by the administration of 20 mL of 1% lidocaine to flush the tube
and ensuring the glucose is in the pleural space, and to provide some local
anesthesia to the parietal pleura.

Twenty-four hours after the intervention, if there is air leak cessation (defined
below), chest tube removal was considered by the surgical team. If an air leak
was still present, no further intervention was planned. The volume of D50
administered was incremental and followed a rule-based escalation, traditional
3+3 design63 (Figure 2): 3 patients had a set dose, and if there were no doselimiting toxicities (Appendix H) or less than 2 moderate toxicities, the next group
of 3 patients went up one increment following review from the Data and Safety
Monitoring Board. In addition, each patient was reviewed on a weekly basis by
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the surgical team to ensure concordance in adverse events (if any) noted. The
empiric increments were 50 mL, 100 mL, 150 mL, and 200 mL. A maximum of 12
patients were to be enrolled.

Figure 2

Traditional 3+3 design (left plot). From Le Tourneau et al.63 SD =

starting dose; DLT = dose-limiting toxicity; RD = recommended dose. This phase
I trial use the thresholds displayed in the right plot.

The 3+3 design was selected as it is commonly used in Phase I drug trials
(notably in oncology) and uses a progressive approach (rule-based) to find the
appropriate dose for further trials or therapeutic uses. The only assumptions are
that the drug of interest has both a dose-efficacy and a dose-toxicity curve. Once
prespecified dose-limiting toxicities are experienced by at least 2 patients, the
escalation stops, and the dose recommended for phase II trials would typically be
the increment just below the one that triggered the toxicities. An issue that can
arise is that titration can be slow, potentially preventing many patients from
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receiving drugs of effective dosage (subtherapeutic) while only very few will
actually receive trialled drugs near the recommended dosage used for phase II
trials. Most trials using this design will have 6 or more thresholds 63. In our case,
the first increment (50 mL) corresponds to the lower end of the range of volumes
administered to patients in the systematic review. Each dextrose 50% syringe
comes in 50 mL volumes; therefore, increments were arbitrarily chosen to be 50
mL throughout this study and that is why the suggested modified Fibonacci
sequence (smaller dose increments as the dose increases) was not followed.
Finally, the highest threshold used was 200 mL as it is one of the commonest
volumes administered in the systematic review. At a volume of 200 mL and
above, some patients seem to experience adverse events, and therefore we
elected not to go higher.

Several variations of the 3+3 design exist, with different rules or accelerated
escalation designs (based on plasma drug concentration for example). The main
advantage of this traditional design is that it is safe, simple to implement and has
a proven track record, being in use for many decades in large studies leading to
drug approval by organizations such the U.S. Food and Drug Administration.

Modelreal-time to establish how quickly the dose can be escalated to reach the phase
II dose quicker. Biostatistical expertise is mandatory. Several assumptions on the
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dose-toxicity curve have to be made beforehand and, if wrong, may fail to reach
the recommended dose for the phase II trial.

For all the aforementioned reasons, the traditional 3+3 design was selected in
the current study.

4.2

DATA AND SAFETY MONITORING BOARD (DSMB)

As mandated by Health Canada, a DSMB was constituted. Four physicians
expert in their field and consultants at LHSC were recruited:
Dr. Richard Inculet, Thoracic Surgery
Dr. Nathan Ludwig, Anesthesia & Perioperative Medicine
Dr. Amanda Berberich, Endocrinology and Metabolism
Dr. Michael Mitchell, Respirology

These individuals were selected for their knowledge in the pulmonary physiology,
the post-operative course after lung resection, the impact of dextrose when
administered in high concentration, the treatment of hyperglycemia and the
treatment of pain. Members of the DSMB have signed a declaration confirming
the absence of any financial or other interest with any of the investigators or
other organizations involved in the study that could represent a potential
perceived or true conflict of interest.
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Communications between the DSMB and the investigators were by secured
email. The DSMB reviewed data from REDCap (secure, web-based, institutionapproved software), along with a narrative of the 3 patients in each threshold to
confirm moving up to the next increment.

The DSMB operated using strict and well-defined halting rules (Appendix H).

4.3

PRIMARY ENDPOINT

The primary outcome of this Phase I study is the safety of intrapleural dextrose
50% as defined by the lack of grade 3, 4 or 5 adverse event at any given D50
volume according to the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 64. Each adverse event has its own criteria to define the
grade of the adverse event (AE). Grade 1 is considered a mild AE, while grade 5
is an AE resulting in death.

The AE were collected by the investigators and transmitted to the DSMB with a
detailed narrative of the AE. Questions from the DSMB were answered. The
DSMB was responsible to approve the final grading of each AE.

4.4

SECONDARY ENDPOINTS

Secondary outcomes include:
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Presence of any adverse event
Persistence (yes/no) of air leak 24, 48 and 72 hours post dextrose
administration, and change in the air leak rate
Pain score at baseline, 1 hour, 3 hours, 6 hours, and 24 hours after
dextrose administration (visual analog scale)
Point-of-care glucose measurement at baseline, 1 hour, 3 hours, 6 hours,
24 hours after dextrose administration
Chest tube output during the first 24 hours after dextrose administration
Length of hospital stay
Duration of chest tube drainage
Need to discharge the patient home with a one-way (Heimlich) valve
Need for an additional chest tube to be inserted after dextrose
administration
Supplemental oxygen requirements
Patient analgesia consumption
Need for any intervention to treat hyperglycemia
Recurrence of air leak

Demographic characteristics (age, gender, smoking status, comorbidities,
diagnosis, type of surgery, surgical approach and the air leak rate pre-D50) were
also collected. The Charlson Comorbidity Index (CCI)65 is a prognostic score
derived from 19 pre-defined comorbid conditions. Each condition has a different
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weight based on the association with 1-year mortality. It is calculated for each
patient.

4.5

AIR LEAK DEFINITION

For
follow using the Medela Thopaz TM digital system (Figure 3 and 4):
-

Air leak
o Air leak equal or more than 40 mL/min for at least 1 hour during the
last 12 hours if the tube is on suction, or
o Air leak equal of more than 20 mL/min for at least 1 hour during the
last 12 hours if the tube is on gravity mode

-

Cessation of air leak
o No record of sustained air leak (1 hour or more) of 40 mL/min or
more for the last 12 hours if the tube is on suction, or
o No record of sustained air leak (1 hour or more) of 20 mL/min or
more for the last 12 hours if the tube is on gravity mode

This definition is based on Gilbert et al. paper 29 which used those criteria in a
randomized controlled trial to decide when to remove chest tubes. Using those
criteria, no chest tube reinsertions for worsening pneumothorax or subcutaneous
emphysema after chest tube removal occurred.
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Figure 3

Digital drainage system, Medela Thopaz TM. There is a sample

port where a needle can be inserted, obviating direct trauma to the chest
tube. Reproduced after obtaining authorization from Medela Canada, Inc.
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Figure 4

Digital drainage system, Medela Thopaz TM. A graph displays the

leak rate over the last 24 hours. Reproduced after obtaining authorization from
Medela Canada, Inc.

4.6

INCLUSION CRITERIA

In order to be eligible to participate in this study, an individual must meet all of
the following criteria:

1. 18 years old or older
2. Lung resection is a wedge, segmentectomy, lobectomy or bilobectomy
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3. Surgery was not performed to induce pleurodesis (no pleural abrasion, no
pleurectomy, no talc)
4. Procedure performed by video-assisted thoracic surgery, or by
thoracotomy
5. Presence of an air leak on the digital draining system on POD#2

Patients who did receive talc as part of their surgery were not invited in this
study, as the effect of concomitant talc plus hypertonic glucose is unknown, and
this was not the purpose of the current trial.

4.7

EXCLUSION CRITERIA

An individual who meets any of the following criteria was excluded from
participation in this study:

1. Large air leak arbitrarily defined as more than 1,000 mL/min
2. Allergy to local anesthetics
3. Hemodynamic instability
4. Untreated coronary artery disease
5. Need for mechanical respiratory support
6. Any other early post-operative complication
7. Immunity disorder
8. Large fluid output arbitrarily defined as over 500 mL in the last 12 hours
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9. Inability to give consent
10. Fasting glucose

14 mmol/L the morning of the intervention (arbitrarily

chosen cutcontrolled)
11. Endocrinology service not available to co-manage patients with either
diabetes, or a fasting blood glucose

7 mmol/L, or HbA1c > 6.5%

12. Postoperative evidence of an active thoracic (lung or pleura) infection with
systemic inflammatory response syndrome (SIRS) (2 or more of
temperature > 38, heart rate > 90, respiratory rate > 20, WBC > 12)

Patients had to be competent to participate to this study, proxy consents were
not allowed. There is a theoretical risk of increased myocardial demand when
pleurodesis is performed due to the inflammatory reaction created, therefore
patients with untreated coronary artery disease were excluded. One concern
raised by Health Canada was the risk of infectious complications, and it was
decided to exclude patients with immunity disorders for this reason.

The last 3 criteria were added after review by Health Canada which was
particularly concerned by the risk of severe hyperglycemia and the effect on
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4.8

STUDY AGENT AND METHOD OF ADMINISTRATION

The glucose solution is manufactured by Hospira, company owned by Pfizer Inc.

00037974). The agent comes in pre-filled 50 mL syringes (AnsyrTM or
LifeShieldTM). It was not possible to use the Ansyr TM II system due to national
shortage in 2019-2020. An equivalent delivery system (LifeShield TM, product
number 04902L50) was therefore used (Lot 04-431-DK, expiry 20210401). Each
syringe was acquired from LHSC pharmacy at a $30.38 CAD unit cost. Thirty-six
syringes were acquired from funds granted by Western University Department of
Surgery (Appendix A). These syringes were stored on room temperature until
their utilization as recommended in the product brochure (Appendix I).

This agent was administered by a single individual (MQ) involved in this study in
a standardized approach. The digital draining system was turned off and hanged
over an intravenous pole, so it sta
one meter. The chest tube was not clamped to avoid creation of a tension
pneumothorax. The patient is placed on a contralateral lateral decubitus position
to facilitate entry of the glucose solution in the pleural space by gravity. The hub
of the digital drain was sterilized with alcohol swabs. Administration of the
solution was performed on a sterile fashion. Lidocaine 1% 20 mL was then
injected to provide topical anesthesia to parietal pleura and to flush the excess of

43

hypertonic glucose from the chest tube. The patient was then asked to move
every 15 minutes from one side to another. After 2 hours, the digital system was
placed again on the ground and suction was applied (-20 cm H 2O).

4.9

STATISTICAL ANALYSES

Paired t-test is used to compare paired, continuous variables (volume of air
leaked, chest tube output) after ensuring normality of the distribution of the
differences using the Shapiro-Wilk test. Repeated-measures ANOVA is used to
analyze glycemia data over various time period. Intention to treat analyses are
performed. A p-value of 0.05 or less is considered statistically significant.

Post-lung resection air leak tends to naturally decrease over time as the leak
seals spontaneously. Comparing the volume of air leaked before and after an
intervention without accounting for that previously stated fact could generate
misleading results. Interrupted time series analysis/segmented regressions can
be used when an outcome variable is measured over time, before and after an
intervention. This quasi-experimental design is typically used in population-based
studies, notably by governments to determine if a policy is effective 66

71

.A
-

-D50. Both the immediate impact on the air leak rate right
after D50 (seen in a change in the intercept of the regression line in the model
post-D50) and the impact on the change of air leak rate over time (slope) can be

44

assessed. This can statistically confirm the impression of efficacy seen on
several patients (Figure 5). A statistical decline in the intercept post-D50 is
clinically interesting and a desired effect (immediate air leak decrease after D50
administration). It is more difficult to interpret the slope

it can become less

negative (closer to 0) after D50 and this would not necessarily mean D50 is
detrimental for the air leak. Therefore, only the immediate impact of D50
(intercept) is analyzed. The R code is found in Appendix L and is adapted from
Professors Haider and Law work72.

SPSS version 26 (IBM Corp. Released 2019. IBM SPSS Statistics for Macintosh,
Version 26.0. Armonk, NY: IBM Corp.), R version 4.0.3 (R Core Team (2020)) 73
and RStudio version 1.3.1093 (RStudio Team (2020)) 74 were used to perform
statistical analyses.
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5

RESULTS

5.1

DEMOGRAPHICS

From March 12, 2020 to December 24, 2020, 176 consecutive patients were
screened for eligibility. The procedures performed were as follow:
-

83 wedge resections

-

78 anatomical lobectomies

-

13 segmentectomies

-

1 bi-lobectomy

-

1 sleeve lobectomy

Of these, 32 fulfilled all inclusion criteria. Of these 32 patients, 17 had at least
one exclusion criteria:
-

6 had an air leak over 1000 mL/min

-

2 patients had respiratory failure post-op and were kept intubated

-

2 were on immunosuppressive medication

-

2 had evidence of post-operative bleeding

-

2 had fever and tachycardia of unknown etiology post-operatively

-

1 had delirium and urinary tract infection post-operatively

-

1 was on chronic antibiotics for a mandible infection

-

1 had severe post-operative bronchospasm
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As such, 15 patients were invited to be enrolled to this study. Of these 15
patients, 12 consented and received intrapleural dextrose 50%. Three patients
were not enrolled for the following reasons:
-

1 refused for personal motives

-

1 could not be enrolled because there were no digital drains available

-

1 could not be enrolled because the researchers were not available to
recruit the patient and administer the study agent

The mean (SD) age was 69.2 (5.1) years old. Women constituted 58% (7/12) of
the patients. A summary of the demographics of the recruited patients is
displayed in Table 3 and 4. Of note, patient #1 and #11 are in fact the same
person who underwent 2 distinct surgeries. No patient had preoperative
diagnosis of diabetes, however one (patient #4) was diagnosed with type 2
diabetes during her hospital stay. All patients had their surgery for oncological
indications.
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Age (years)

Mean (SD)
Median [Q1 Q3]
N
69.2 (5.1)

Gender M:F

5:7

Variable (n=12)

Smoking status
Ex-smoker

7/12 (58%)

Non-smoker

2/12 (17%)

Smoker

3/12 (25%)

CCI

3.5 [2

4.5]

Diagnosis
Lung metastases

3/12 (25%)

Lung nodule

3/12 (25%)

Lung cancer

4/12 (33%)

Cancer recurrence

2/12 (17%)

Surgery
Lobectomy

8/12 (67%)

Wedge

4/12 (33%)

Approach
Thoracotomy

9/12 (75%)

VATS

3/12 (25%)

Air leak pre-D50 (mL/min)

Table 3

115 [50

332.5]

Patients demographic. CCI = Charlson Comorbidity Index; VATS =

video-assisted thoracic surgery; D50 = dextrose 50%; SD = standard deviation.
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Patient #

Group (mL)

Volume
received (mL)

Age (years)

Sex

CCI

1

50

50

72

F

6

2

50

50

66

M

6

3

50

50

66

M

4

100

100

63

5

100

100

6

100

7

Smoking
status

Diagnosis

Surgery

Approach

Air leak pre-D50
(mL/min)

lung metastases

lobectomy

thoracotomy

50

lung metastases

lobectomy

thoracotomy

30*

3

ex-smoker
nonsmoker
smoker

lung nodule

wedge

VATS

400

M

4

smoker

lung cancer recurrence

lobectomy

thoracotomy

110

67

F

4

ex-smoker

lung cancer

lobectomy

thoracotomy

120

100

71

M

2

smoker

lung cancer

lobectomy

VATS

190

150

150

81

F

4

lung cancer

lobectomy

thoracotomy

490

8

150

150

72

M

2

lung nodule

wedge

thoracotomy

310

9

150

150

69

F

3

ex-smoker
nonsmoker
ex-smoker

lung nodule

wedge

thoracotomy

590

10

200

10

69

F

2

ex-smoker

lung cancer recurrence

lobectomy

thoracotomy

50

11

200

35

72

F

6

ex-smoker

lung metastases

wedge

VATS

100

12

200

200

62

F

2

ex-smoker

lung cancer

lobectomy

thoracotomy

40

Table 4

Individual patient demographics. CCI = Charlson Comorbidity index; D50 = dextrose 50%; VATS = video-

assisted thoracic surgery. *This patient fit the definition of air leak, but the last value recorded before administration of
dextrose was 30 mL/min. Those two patients did not receive the full volume as described in manuscript.
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5.2

PRIMARY OUTCOME

All adverse events, including grade and relationship with the intervention are
displayed in Table 5. Below are the details of each adverse event.

Patient #1 did not experience any adverse event.

Patient #2 was found to have a knee cellulitis on POD#3. On further
questionnaire, it was found that the patient already had a cellulitis preoperatively,
but it was not disclosed to the investigators nor the medical team. The patient
was therefore placed on antibiotics. No other adverse event noted.

Patient #3 had a sputum culture ordered by the nurse on POD#2, without this
being disclosed to the investigators nor the medical team. The patient was then
enrolled into the study and glucose was administered. On POD#3, it was found
that the sputum was positive for 2 bacteria, and intravenous antibiotics were
started. It was not clear if the patient was just colonized with those germs, or if he
had a true pneumonia. The Infectious Diseases team was consulted. This
adverse event was not due to the intervention, as the sputum culture preceded
injection of D50. This patient recovered uneventfully from the pneumonia.

.

51

Patient #

Group

1

50

Volume received
(mL)
50

2

50

3

50

Adverse event

Grade

Relationship

None

n/a

n/a

50

Knee cellulitis

2

not related

50

Pneumonia

3

not related

Diarrhea - C. difficile

1

not related

4

100

100

None

n/a

n/a

5

100

100

Atrial fibrillation

2

unlikely to be related

6

100

100

None

n/a

n/a

7

150

150

None

n/a

n/a

8

150

150

None

n/a

n/a

9

150

150

None

n/a

n/a

10

200

10

Chest wall pain

3

definitely related

11

200

35

Cough

1

definitely related

12

200

200

Atrial fibrillation

2

unlikely to be related

Table 5

Adverse event
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On POD#6, the patient was found to have diarrhea and was in fact positive for C.
difficile colitis. This was not felt to be related to the intervention, but rather from
the use of IV antibiotics.

Finally, an additional chest tube was placed on POD#3, or 22 hours after the
dextrose was administered. The original chest tube placed in the operating room
was deemed to be position-dependent by the medical team prior administering
the dextrose, as reflected by the presence of subcutaneous emphysema a few
hours post-operatively and the significant variation in the air leak rate ranging
from 0 to 400 mL/min. The insertion of an additional chest tube was not felt to be

the original chest tube.

Patient #4 did not experience any adverse event.

Patient #5 had a fasting glucose of 7.7 mmol/L, a HbA1c of 6.2%, and a preintervention glycemia of 12.6 mmol/L. Given these values, Endocrinology was
-existing prediabetes/mild ty
sliding scale. She received 3 units subcutaneously, and then another 2 units.
This was not classified as an adverse event. Endocrinology recommended a
follow-up with the patient General Practitioner on discharge to manage her type 2
diabetes mellitus.
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The patient developed atrial fibrillation on POD#4 (2 days after dextrose
administration). She remained asymptomatic and hemodynamically stable and
was fully converted back to sinus rhythm after receiving metoprolol 12.5 mg oral.
This was classified as a grade 2 adverse event
the intervention.

Patient #6 did not experience any adverse event.

Patient #7 did not experience any adverse event. An additional chest tube had to
be inserted for a basal space noted on CXR POD#15.

Patient #8 did not experience any adverse event. He tripped on the chest tube 26
hours after dextrose administration, which led to disconnection of the chest tube
from the digital drain. When reconnected, there was a new air leak (Figure 5-H,
see below).

Patient #9 did not experience any adverse event.

Patient #10 did experience severe pain after administration of only 10 mL of
hypertonic glucose. The investigators stopped administration of the intrapleural
drug, and placed back the tube on suction, aspirating the glucose. Once the
glucose was outside of the pleural space, the pain subsided. This grade 3
adverse event is definitely related to the intervention and resolved quickly after
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the glucose was evacuated. This patient did not have another attempt at D50
insertion.

Patient #11 did experience mild to moderate cough after administration of an
initial volume of 20 mL of hypertonic glucose. The investigator paused and
resumed injection of another 15 mL when the administration was stopped
completely for fear that too much of the hypertonic solution may enter the lung
parenchyma. The patient was able to taste sugar in her mouth. The chest tube
was kept above the patient for the usual 2 hours, and then placed back on the
ground and on suction. This grade 1 adverse event is definitely related to the
intervention and ceased when we stopped administering the glucose.

Patient #12 did experience asymptomatic atrial fibrillation on postoperative day 3
(24 hours after the intervention). The cardiologist mentioned that this was most
likely pre-existing from before the surgery as she had pre-syncopal episodes in
the past.

5.3

SECONDARY OUTCOMES

5.3.1 DESCRIPTIVE ANALYSES

Secondary outcomes are displayed in Table 6 and 7. For the whole cohort, the
median (IQR) length of stay was 6.9 (5.3
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8.7) days. Patients were discharged

with a one-way valve in 33% (4/12). The median (IQR) time from D50
administration to last chest tube removal was 6.6 (2.6

17.2) days. Mean (SD)

chest tube output during the first 24 hours after D50 administration was 365 (246)
mL. No patient was discharged on home oxygen, nor readmitted after being
discharged, nor experienced recurrent air leak. Two patients (17%) required
additional chest tube after the intervention.

The evolution of the air leak rate, the glycemia and the pain level over time is
displayed in Figure 5 for each patient. The vertical red line denotes when D50
was administered in the pleural space. Administration of intrapleural glucose did
not increase pain as assessed by empirically inspecting the graphs. Most
patients (9/12) experienced increase in glycemia (0.1 to 8.2 mmol/L) 1 hour after
intrapleural administration but this was not clinically significant. Only one patient
(1/12) received additional treatment to control the glycemia (subcutaneous
insulin).

There was no reduction in the amount of air leak with a volume of 50 mL of
dextrose 50% as shown in Figure 5 A-C. However, a flattening of the air leak
curve was noted at a volume of 100 mL (Figure 5 D-F), and this was even more
pronounced at a volume of 150 mL (Figure 5 G-I). Flattening of the air leak curve
was also noted in the group 200 mL (Figure 5 J-L).

56

Mean (SD)
Median [Q1 Q3]
N
6.9 [5.3 8.7]

Variable (n=12)
Length of stay (days)
Time from D50 to last chest tube removal (days)

6.6 [2.6

17.2]

Output 24h post-D50 (mL)

365 (246)

Glycemia pre-D50 (mmol/L)

7.4 (1.9)

Glycemia 1h post-D50 (mmol/L)

10 (3.4)

Heimlich valve

4/12 (33%)

Additional chest tube required

2/12 (17%)

Additional treatment for hyperglycemia

1/12 (8%)

Empyema

0

Discharged on home O 2

0

Readmission

0

Recurrent air leak

0

Table 6

Secondary outcomes. D50 = dextrose 50%. SD = standard deviation.
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Patient
#

LoS
(days)

Time from D50 to last chest
tube removal (days)

Output 24 h
post-D50 (mL)

Glycemia preD50 (mmol/L)

Glycemia 1 hr postD50 (mmol/L)

glycemia
(mmol/L)

Heimlich
valve

Additional
chest tube?

Additional treatment
for hyperglycemia

Home
O2?

Readmission?

Recurrent air
leak?

1

5.3

9.9

325

7.5

6.1

-1.4

Yes

No

No

No

No

No

2

7.4

4.9

300

7.2

5.9

-1.3

No

No

No

No

No

No

3

9.4

18.8

0

6.3

7.3

1

Yes

Yes

No

No

No

No

4

11

8.1

600

9

10.4

1.4

No

No

No

No

No

No

5

6

1.7

325

12.6

14.5

1.9

No

No

Yes

No

No

No

6

4.3

2.0

500

7.3

11.9

4.6

No

No

No

No

No

No

7

19.4

17.0

775

6.7

14.9

8.2

No

Yes

No

No

No

No

8

6.3

17.8

400

7.8

9.2

1.4

Yes

No

No

No

No

No

9

8.1

24.8

200

6.1

11.4

5.3

Yes

No

No

No

No

No

10

5.3

2.8

100

6.4

*

*

No

No

No

No

No

No

11

3.3

0.7

125

6

6.1

0.1

No

No

No

No

No

No

12

8.5

5.0

385

5.3

12.7

7.4

No

No

No

No

No

No

Table 7

Individual patient secondary outcomes. LoS = Length of stay; D50 = dextrose 50%. *indicates missing data.
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A. Patient #1
Figure 5 (A-C, 50 mL group)

B. Patient #2

C. Patient #3

Top graph shows relationship between air leak rate (blue line) and time, and glycemia (orange

line) and time. Bottom graph shows relationship between pain level and time. Vertical red line represents D50 administration
in the pleural space.
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D. Patient #4
Figure 5, continued (D-F, 100 mL group)

E. Patient #5

F. Patient #6

Top graph shows relationship between air leak rate (blue line) and time, and

glycemia (orange line) and time. Bottom graph shows relationship between pain level and time. Vertical red line represents
D50 administration in the pleural space.
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G. Patient #7
Figure 5, continued (G-I, 150 mL group)

H. Patient #8

I. Patient #9

Top graph shows relationship between air leak rate (blue line) and time, and

glycemia (orange line) and time. Bottom graph shows relationship between pain level and time. Vertical red line represents
D50 administration in the pleural space.
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J. Patient #10
Figure 5, continued (J-L, 200 mL group)

K. Patient #11

L. Patient #12

Top graph shows relationship between air leak rate (blue line) and time, and

glycemia (orange line) and time. Bottom graph shows relationship between pain level and time. Vertical red line represents
D50 administration in the pleural space. Patients #10 and #11 each received less than 200 mL of D50 (see text).
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5.3.2 EFFECT OF INTRAPLEURAL DEXTROSE ON THE AMOUNT OF AIR
LEAKING FROM THE LUNG

The volume of air leaking out of the lung can be approximated using the
trapezoidal rule75 (Appendix J). For each patient, the last 24 hours preceding
administration of dextrose was calculated, along with the following 24 hours.
Patients #1-2, #4-7 and #9 had enough data to calculate the amount of air
leaking for 24 hours prior and after dextrose administration. Patient #3 did not
have meaningful data before dextrose administration and was therefore excluded
for the purpose of this analysis. Patient #8 disconnected the chest tube 22.9
hours after dextrose was administered (Figure 5-H), and therefore only this time
window was used prior and after dextrose insertion to calculate the amount of air
prior to dextrose
administration (Figure 5-J)
dextrose administration (Figure 5-K). The volume of air leaking that was
calculated for each of these 2 patients was adjusted accordingly to use the same
time period before and after dextrose (4.1 hours for patient #10, 11.6 hours for
patient #11). These patients are analyzed as per the intention to treat design.

Individual patient data is presented in Figure 6 (organized according to D50
volume).
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Figure 6

Volume of air leaking out of the chest in the 24 hours preceding (blue) or following (red) dextrose administration.

For patients #8, #10 and #11, a 22.9 hours, 4.1 hours and 11.6 hours window was used (see text for details).
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Figure 7 shows the effect of intrapleural dextrose on the volume of air escaping
the lung in the 24 hours (22.9 hours for patient #8, 4.1 hours for patient #10, and
11.6 hours for patient #11) before/after dextrose administration. There was a
statistical difference in the mean volume leaked before compared with after
dextrose administration (221 vs 31 L, p=0.013). Subgroup analysis is shown in
Figure 8. Using again paired t-test, statistical differences were found in the
groups D50 100 mL and D50 150 mL (194 vs 31 L, p=0.028 and 503 vs 31 L,
p=0.036 respectively).

**

Figure 7

Mean volume of air leaked (L) in the cohort before or after

administration of D50. ** denotes statistical significance. All patients except
patient #3.
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**

Figure 8

**

Mean volume of air leaked (L) in the cohort before or after

administration of D50 in each subgroup. ** denotes statistical significance.

Figure 5 showed the relationship between the time after the surgery and the air
leak rate for each patient, with a vertical bar denoting when D50 was
administered. There seems to be an immediate decrease in the air leak rate
following D50 in patients #5 to #12. This decrease was statistically significant
only for patients #7, #8 and #11 as shown in Figure 9.
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Figure 9, 50 mL group (patients #1-2)

Relationship between air leak rate and time after

surgery, before and after D50. Raw data from the digital drain is displayed on the left, and data
analyzed using interrupted time series method is displayed on the right. Shaded area represents 95%
confidence interval. The impact of D50 is not statistically significant for patient #1 (p=0.651), and is
statistically significant for patient #2 (p=0.010).
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Figure 9, continued (100 mL group, patients #4-6)

Relationship between air leak rate and

time after surgery, before and after D50. Raw data from the digital drain is displayed on the left,
and data analyzed using interrupted time series method is displayed on the right. Shaded area
represents 95% confidence interval. The impact of D50 is not statistically significant for patient #4
(p=0.133), patient #5 (p=0.392) and patient #6 (p=0.336).
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Figure 9, continued (150 mL group, patients #7-9)

Relationship between air leak rate and

time after surgery, before and after D50. Raw data from the digital drain is displayed on the left,
and data analyzed using interrupted time series method is displayed on the right. Shaded area
represents 95% confidence interval. The impact of D50 is statistically significant for patient #7
(p<0.001), patient #8 (p=0.002) but not for patient #9 (p=0.442).
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Figure 9, continued (200 mL group, patients #11-12)

Relationship between air leak rate and

time after surgery, before and after D50. Raw data from the digital drain is displayed on the left,
and data analyzed using interrupted time series method is displayed on the right. Shaded area
represents 95% confidence interval. The impact of D50 is statistically significant for patient #11
(p=0.007) but not for patient #12 (p=0.428). Patient #10 was excluded as only 2 time points were
available pre-D50.
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5.3.3 EFFECT OF THE INTRAPLEURAL DEXTROSE ON THE CHEST TUBE
FLUID OUTPUT FROM THE PLEURAL SPACE

For each patient, the 24 hours chest tube fluid drainage was compared before
and after administration of D50. Patient #11 had her chest tube removed 18
hours after D50, and therefore only the output of the preceding 18 hours was
taken into consideration. Figure 10 shows the impact of D50 on the chest tube
fluid output. There were no statistical differences (282 vs 365 mL, p=0.198).
Subgroup analyses also did not show any differences (Figure 11). Patientspecific changes in the chest tube output are displayed in Figure 12.
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Figure 10 Chest tube output in the 24 hours before and after D50
administration

Figure 11

Chest tube output in the 24 hours before and after D50

administration, per subgroup
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Figure 12

Chest tube output in the 24 hours before and after D50 administration, per patient
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5.3.4 EFFECT OF THE INTRAPLEURAL DEXTROSE ON THE GLYCEMIA

For each patient, glycemia was measured minutes before dextrose administration
(baseline), at 1 hour, 3 hours and 6 hours. Findings are displayed in Figure 5
(patient-specific), and in Figure 13 as a mean for the 11 patients for which data
was available (Patient #10 did not have glycemia recorded after D50
administration). A repeated-measures ANOVA determined that mean glycemia
differed significantly across the four time points (F(3, 30) = 5.498, p=0.004). A
post hoc pairwise comparison using the Bonferroni correction showed an
increased glycemia between baseline and 1 hour after D50 administration (7.4 vs
10.0 mmol/L), but this was not statistically significant (p=0.156). Therefore, we
can conclude that the apparent transient increase in blood sugar following
intrapleural D50 is not statistically significant in our cohort. This could be due to
the small size of our cohort resulting in a lack of statistical power.
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Figure 13

Glycemia at various points before and after administration of

D50
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6

DISCUSSION AND CONCLUSION

6.1

DISCUSSION

Air leaks following lung resection are a cause of prolonged hospital length of
stay, morbidity and increased costs. Preoperative interventions to prevent them
are scarce. Some may benefit from being weaned off steroids, or their nutritional
status optimized 76, but patients who would actually benefit from these actions are
in the minority. Patients with severe bullous emphysema are sometimes offered
alternative treatment such as stereotactic beam radiation therapy as a way to
avoid the morbidity associated with surgical resection with mixed results 77.

Intraoperative prevention of air leaks involves meticulous fissure-less dissection,
minimizing residual space, and sometimes the judicious use of sealants 78,79.
Benefit in the reduction of postoperative air leaks have been shown on severe
emphysematous patients with bovine pericardium reinforced staple lines 80.

Optimal chest tube management (suction or not) after lung resection is still
matter of debate81. The European Society of Thoracic Surgeons Early Recovery
After Surgery (ERAS) consensus recommends against the routine use of
suction82, but comments that the available evidence is conflicting.
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When there is persistent air leak postoperatively, several strategies including
observation-only, placement of a one-way valve, bedside chemical pleurodesis,
blood patch, reoperation with possible muscle flap or pneumoperitoneum are
options available to the clinician 83. All these approaches have their pros and
cons. As mentioned in the Literature Review, there are several agents used for
chemical pleurodesis. Hypertonic glucose has emerged as an agent which may

have the bad publicity talc had in recent years 59,84. Patients undergoing lung
cancer resection often have surgery as part of a multimodality plan of care and it
is critical that they avoid post-operative infectious complications occasionally
associated with prolonged air leaks.

The mechanism in which hypertonic glucose may induce pleurodesis is unknown.
Pleurodesis often involves a systemic reaction leading to increased erythrocyte
sedimentation rate, C-reactive protein, leukocyte count, and a febrile state. Ukale
et al. showed that the degree of patient systemic response to either talc or
quinacrine correlated with pleurodesis success 85. Teixera37

39,86,87

et al. worked

extensively on the physiology of pleurodesis in their experiments with New
Zealand rabbits using talc or silver nitrate. Following introduction of a sclerosing
agent in the pleural space, damage to mesothelial cells occur. This leads to
neutrophilic exudate and secretion of several cytokines (IL-8, VEGF and TGF- 1).
This in turns alters the balance between metalloproteinases and plasminogen
activators and affects
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Pleural fibrosis becomes evident one week after the insult. Pleural adhesions are
still maturing at 4 weeks while the active microscopic pleural inflammation is
already declining. It is unclear how hypertonic glucose may induce pleurodesis.
The osmolarity of the 50% glucose solution used in this trial is 2526 mOsm/L,
and a pH of 4.2. This is in contrast to plasma osmolarity in the range of 275
299 mOsm/L. Direct mesothelial cell damage may occur, as mentioned above.
This 50% glucose solution, while liquid, also has the property to
syrup. Another mechanism of how this hypertonic solution seals air leaks could
be by mechan

plug

While the first documented use was reported in 1906, hypertonic dextrose is still
not very commonly used compared to other chemical pleurodesis agents

it is

unclear why. We postulate practitioners view other agents as more aggressive
and irritant for the pleura and thus leading to better pleurodesis. Our systematic
review showed that the dextrose concentration, volume, duration, frequency,
timing, and use with additional adjuncts varied greatly. In this era where ERAS is
promoted, treatment of air leaks by an agent widely available, easy to store, safe,
and effective is encouraged.

6.1.1 ABOUT THE OUTCOMES

This study

verse events. The Data

and Safety Monitoring Board rigorously assessed all reported event, evaluated
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the relationship with the intervention (administration of glucose) and then issued
recommendation as to whether continuation of the study was possible. A
member of the DSMB is also a thoracic surgeon who attended the weekly
Thoracic Surgery review of adverse events, further consolidating the oversight of
this Board on this trial. A DSMB halting rule chart was available to guide them in
their recommendation.

In our cohort, no major or severe adverse event was noted. Two patients had an
episode of atrial fibrillation on POD#3-4, or 1-2 days after receiving the glucose.
Supraventricular arrhythmias are common after lung resection. In these particular
instances
, and a cardiologist stated that this tachyarrhythmia was probably
preexisting the surgery. Two non-dose related adverse events happened in the
200 mL group. Patient #10 had immediate, severe chest wall pain after injecting
only 10 mL of the solution. The pain was severe enough that the patient wished
to stop the procedure. The solution was aspirated from the chest and the pain
subsided immediately. It is not clear why this patient experienced this degree of
discomfort. One hypothesis is that she must have had some pleuritis where the
tube abutted. Patient #11 developed clinically significant cough during
administration of the hypertonic solution and could taste it in her mouth. This was
the case despite the air leak rate being only 100 mL/min which was in the
acceptable range. Leaks over 1,000 mL/min were deemed too large, and thus a
surrogate of a large defect in the lung parenchyma with higher potential for
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aspiration of the pleural fluid into the lung and the airway, increasing the risk of
pneumonitis and/or respiratory distress. It is worth mentioning that those 2
adverse events were triggered at a volume inferior to the minimal increment
tested (50 mL). Both patients did well, and it highlights the clinical judgement
required when administering intrapleural solutions. One strategy that could have
possibly helped mitigating both situations would have been to administer local
anesthesia (lidocaine) prior to D50 insertion in the chest. Lidocaine was selected
to be administered following the D50 in order to flush the tube of any residual
dextrose solution, out of the theoretical apprehension that the chest tube could
possibly clog if this hypertonic solution sits for 2 hours before the tube placed
back on suction. Administering the lidocaine first could block the nociceptive
stimulus triggered by dextrose on the parietal pleura. However, if a sizable
pleuroalveolar communication exists, lidocaine could also blunt the coughing
reflex leading to more dextrose ultimately going into the lung and airway. We
propose an approach that would administer 10 mL of lidocaine first, and then
flush the tube with another 10 mL after introducing the dextrose.

Intrapleural glucose led to a significant reduction in the volume of air leaked. Post
hoc exploratory analyses were performed. For the entire cohort, the reduction in
the mean volume leaked was 86% (from 221 L to 31 L). There appeared to be a
dose-response effect (Figure 6). The effect of the glucose on air leak reduction
was assessed both empirically inspecting the air leak rate over time graphs
(Figure 5) and statistically (Figure 9). The decision to remove a chest tube after
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lung surgery depends mostly on a reduction of the air leak, but it is unclear how
much air can still be leaking before the chest tube can be removed without
needing to reinsert one. Gilbert et al.29 have suggested that a chest tube can be
removed safely with an active air leak of up to 30 mL/min (or 43.2 L / 24 hours).
Our trial suggests that D50 does reduce the volume of air leaks after lung
surgery and may have a role in expediating the removal of chest tubes. A volume
of 150 mL appeared to be optimal.

Our trial did not address the effect of repeated intrapleural dextrose
administration, but it is theorized that it could lead to further reduction in the
volume of air leaking from the lung parenchyma. In the systematic review, 2
papers6,52 described repeated administration after a first fail attempt in
retrospective cohorts. Sumitomo described that the 2 patients who had repeated
D50 sealed their leak. Additionally, Fujino described reported that out of 18
patients who did not seal their leak immediately after a first attempt, 8 had a
successful second injection.

The outcome used was the volume of air leaked and not the air leak rate as while
excellent interobserver reliability using the Medela Thopaz TM was reported28, our
data shows that there can be significant variation of the air leak rate over time,
both before and after the pleurodesis. A patient with several spikes of air leak
overnight who would then have a much smaller leak when assessed by the
medical team a few hours later may not have his tube removed by fear of the
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leak reactivating. This scenario is not that uncommon, and perhaps using the
total volume of air leaked in a certain time frame may be a better metric in certain
circumstances than looking only at the flow. The question then would be when,
after dextrose injection, would the air leak rate be documented and compared to
the pre-pleurodesis value to ensure success of the air leak resolution. Chest tube
are typically removed when the fluid output falls under a certain threshold. Since
the chest tube purpose is to evacuate both fluids in the pleural space and the air
potentially leaking from the lung, it made sense to treat both states as volumes
for statistical considerations.

Contrary to some reports6,53, there were no dramatic increase in the chest tube
fluid output following dextrose administration. Fujino reported on a patient who
drained 780 mL of fluid in the 2 hours following D50 after the tube was placed
back on suction. The mean volume drained after successful pleurodesis was 605
mL, and this was significantly higher than in patients who did not have successful
pleurodesis (297 mL). Takanashi reported on a 97-year-old man with
spontaneous pneumothorax who received 400 mL of D50, and subsequently
drained 1,960 mL of fluid over 4 hours. This led to severe dehydration, acute
kidney injury and resultant ischemic colitis from hypoperfusion. The patient was
treated conservatively and recovered. We did not see such increase in the chest
tube output following D50 administration in the present study, but this may be
due to the relative lower volume used in this trial compared to others.
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Most patients had a slight increase in their glycemia, although it was not
statistically significant, and it reverted back closer to baseline within 3 hours. This
is similar to Tsukioka et al. findings 8. In our trial, nobody had preexisting
diabetes. One patient was diagnosed as having diabetes by Endocrinology the
day she was enrolled in the study. She required a minor amount of supplemental
subcutaneous insulin (total of 5 units in 2 divided doses) and there were no
clinically significant adverse events.

6.1.2 LIMITATIONS

Our study has some limitations. This is a small cohort of patient and hence, any
statistical analyses are subject to a lack of power. The COVID-19 global
pandemic was declared just one day prior to this study started to screen patients.
Operating room shutdown led to decrease surgical volumes. To compensate the
lack of OR time, we had started doing cases by thoracotomy instead of videoassisted as these surgeries are typically performed faster open. We anecdotally
noticed that this led to a decline in the incidence of air leaks, presumably due to
gentle retraction of the lung parenchyma during thoracotomy compared to tight
grasp of a thoracoscopic grasper. The lack of postoperative air leaks hindered
patient accrual.

There are some missing data that limit our ability to perform some analyses.
However, we believe our results are robust because the safety profile of D50 at
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the volume used in the current prospective trial corresponds to findings from
retrospective studies. In addition, some missing data are in fact on air leak flow
due to early chest tube removal secondary to rapid pleurodesis.

This study is performed in one center only, and better external validity could be
achieved if a multicenter trial is performed. We are hoping to invite other centres
in the next phase of this research.

6.1.3 STRENGTHS

This study is one of only two to prospectively evaluate the safety of the bedside
administration of hypertonic glucose to treat post-operative air leak. The other
prospective study on the topic was performed by Albargawi et al. also from our
institution and has only presented in abstract9. The current study has several
differences. First, this is a Phase I trial assessing safety and collecting data to
assist in designing a phase II trial down the road. Information on air leak
resolution, chest tube removal or length of stay are all data that will be useful for
sample size calculation and research planning. Rigorous oversight by regulatory
agencies (Health Canada) and a DSMB was required. Secondly, we used a rulebased escalation, traditional 3+3 design to move to the next dose threshold. This
approach is considered the standard and is commonly used when new drugs
need to be approved, notably in oncology. This makes the methodology very
robust.
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Our study prospectively collected data. To minimize selection bias, all
consecutive patients were screened and considered for the trial. There were no
patients lost to follow-up. There was consistent and thorough reporting and
oversight by a diverse group of experts on the DSMB throughout the study.

We used a commercially available product from Hospira/Pfizer as our study
agent rather than requiring our hospital pharmacy to prepare the D50. This was
considered superior because: it was more convenient in terms of storage, more
convenient for the researchers to have immediate access to the drug including
during weekends, it was more cost effective by not requiring a pharmacy
technician to prepare an immediate-use injectable for research purposes while
clinical work may have been requested at the same and we secured doses for
the whole Phase I trial.

The process in which the drug was administered was very standardized, starting
by confirming the presence of a leak using a digital drain system, administering
the drug to all patients on POD#2, having only one researcher who obtained
consent and administered the study agent to be the most consistent possible.
This leads to reliable data, with good internal validity.
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6.2

FUTURE DIRECTIONS

Exploratory analyses in this cohort have shown that there is some efficacy in the
use of intrapleural administration of dextrose 50% to treat air leaks. We arbitrarily
elected to dispense this drug once, but perhaps there could be a role for
repetitive administration of intrapleural glucose. Additionally, intrapleural glucose
was administered intraoperatively in a few papers, including in Tsuboshima47 et
al. trial where 50 mL of D50 was sprayed over the staple line and an absorbable
mesh to prevent recurrent spontaneous pneumothoraces. This may have the
drawback to expose some patients to D50 while they may not have needed.

Performance of bedside pleurodesis as early as POD#1 instead of POD#2 could
be done. This would potentially lead to further reduction of the hospital length of
stay. Administration of D50 on POD#2 was chosen for practical reasons: due to
the scarcity of Medela ThopazTM at our institution when the trial was designed,
we were apprehending that too many of these digital drains may be used,
preventing patients with other clinical indications (large leak and need to
ambulate, prolonged air leak with lung collapse when off suction) from being able
to utilize them. We now have access to more of these drains. In addition, this trial
primarily assessing safety

performing the intervention later in the postoperative

course prevented recruiting patients who may have had unrelated adverse
events that would have happened between POD#1 and POD#2. Out of the 32
patients who met inclusion criteria, 4 were excluded for adverse event that could
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have been attributed to D50 but would in fact not be linked to the intervention (2
had fever/tachycardia of unknown etiology on POD#1 or early POD#2, 1 had
severe post-operative bronchospasm late POD#1

early POD#2, and 1 had

delirium and urinary tract infection on POD#1). Due to the design of our Phase I,
those events may have jeopardized the ability to pursue to study further, even if
the plausibility of a relationship between D50 and those events is small. Adverse
events would be recorded during a Phase II trial, but this would not be the
primary outcome. In addition, initial concerns were raised on whether postoperative bleeding would clog tubing of the Medela Thopaz easily (the diameter
is smaller than the standard analog drainage system). This worry did not
materialize. Lastly, performing the intervention on POD#2 meant being able to
introduce the study to patients on POD#1, and have time to obtain consent by
POD#2. Since we now have a track record using D50, patients may be able to
give consent sooner.

6.3

CONCLUSION

In conclusion, intrapleural administration of glucose 50% at a volume ranging
from 50 mL to 200 mL on post-operative day 2 after lung resection surgery to
treat air leaks appear safe and well tolerated. Optimal dose is 150 mL.
Precautions during the intrapleural administration have to be taken to detect and
prevent increased chest discomfort or severe cough. Further work is needed to
confirm safety and establish efficacy of hypertonic glucose to seal air leaks.
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CHAPTER 7
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7

PROPOSAL FOR A PHASE II TRIAL

The next phase is to evaluate the efficacy of intrapleural glucose in treating postlung resection air leaks in a randomized pilot Phase II trial. To our knowledge,
this would be the first prospective randomized trial assessing efficacy and
effectiveness of D50 in reducing prolonged air leaks in patients undergoing lung
resection.

7.1

HYPOTHESIS AND OBJECTIVES

Question:

the

administration of 150 mL of

50

air leak

Hypothesis: Intrapleural D50 at a volume of 150 mL repeatable once (2
injections maximum) is effective at treating post-lung resection air leaks.
Objective: To evaluate if the postoperative intrapleural instillation of D50 in
patients undergoing surgical lung resection will decrease the duration of chest
tube drainage (air leak resolution) compared to placebo.

7.2

PROJECT PLAN

To further define efficacy of intrapleural dextrose in sealing post-operative air
leaks, we would like to perform a multicentre, double-blind, randomized
controlled trial between administration of intrapleural dextrose vs. placebo. Trial
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flowchart is detailed in Figure 14. Twenty patients per group are required. This
phase II trial would have the following PICO:

Population:
Adult patients undergoing lung resection surgery for cancer
The air leak would need to be present and confirmed on POD#1 (at least 100
mL/min documented)

Intervention:
Intrapleural administration of 150 mL of D50 on POD#1
D50 can be repeated on POD#2 if there is still evidence of air leak

Comparison:
Intrapleural administration of 150 mL of placebo (normal saline) on POD#1, to
be repeated on POD#2 if there is still evidence of air leak

Outcome:
The primary outcome will be the duration of chest tube drainage (DCTD),
defined as the time between completion of surgery and last chest tube
removal
Two secondary outcomes of importance are the time to last chest tube
removal (TCTR), defined as the time between intrapleural injection and last
chest tube removal, and the time to air leak resolution (TALR), defined as the
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time between intrapleural injection and the air leak volume in 12 hours falling
under a predefined threshold depending on if intrapleural suction is applied or
not
Additional secondary outcomes would include quality of life using the
Functional Assessment of Cancer Therapy-Lung (FACT-L)88, the EQ-5D89
and the SF-3690 instruments, pain levels, narcotics consumption, adverse
events (Ottawa Thoracic Morbidity & Mortality System)91 and their relationship
with the study agent, and all the other endpoints collected during our Phase I
trial

Figure 14

PLUG-2 trial flowchart
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7.3

SAMPLE SIZE CALCULATION AND DATA ANALYSIS

A peak air leak over 100 mL/min has been shown to be a predictor of prolonged
air leaks (OR 4.97) by Takamochi et al. 92, and thus increased morbidity. This
population is the one we are planning to target in our Phase II study using 150
mL of intrapleural dextrose 50%, volume that should be effective at stopping the
air leak and reducing the duration of chest tube drainage (DCTD).

Chest tubes can be safely removed on patients if, over the last 12 hours, air leak
rate has dropped to < 40 mL/min if the drain is on suction, or < 20 mL/min if the
drain is not on suction as per Gilbert et al. 29 work.

Four individuals in our Phase I study received a volume of D50 > 150 mL. All
those patients had a peak air leak > 100 mL/min before D50. Effect on the air
leak was remarkable. They would have been included in the Phase II study. Their
air leak rates have decreased dramatically after injection of D50. Using Gilbert
criteria for safe chest tube removal and accounting for chest tube removal in the
morning as standard safe practice, those 4 patients would have kept their chest
tubes a mean duration of 3.04 days (SD 0.48) since completion of surgery. This
is deemed the expected mean DCTD in the experimental arm (D50).

In Takamochi et al., 27 patients had a peak air leak > 100 mL/min. Mean + SD
duration of chest tube placement in this group was 5.9 + 2.9 days. Of note, 48%
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of these patients did have prolonged air leak. This group is considered the
control arm for sample size calculation purposes. The aforementioned mean (5.9
days) is likely conservative as some patients may have received sclerosing
agents if they were leaking for more than 5 days. The mean DCTD of a true
control group (placebo only) is probably higher (resulting to an even larger
difference between Takamochi paper and our D50 Phase I trial).

We use the following formulas to calculate the sample size for two independent
samples, continuous outcomes (Clinical Research for Surgeons93 and Pr Lisa
Sullivan course94):

d effect size. An
are desired.

of 0.05 and a

of 0.2 for a power of 80%

reflects the standard deviation of the outcome variable. This is not

known, but can be estimated by generating S p, the pooled estimate of the
common standard deviation derived from the 2 aforementioned studies (D50
Phase I trial and Takamochi paper). There, n 1 is the sample size of the D50 study
(4), s1 is the SD of the D50 study (0.48), n 2 is the sample size of Takamochi
group (27), s2 is the SD of Takamochi group (2.9). The S p generated is 2.75.
Using this Sp in lieu of

and with

=

1

2

where

1 is

3.04 and

obtain a sample size per group of 14.5 (rounded up to 15).
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2 is

5.90, we

Alternative calculation is performed to evaluate the sample size needed to reach
a power of 80% to detect a difference of 2.86 days (5.90
chest tube placement with an
= 3.04,

2

= 5.90,

3.04) in the duration of

of 0.05. The Cohen d

1

= Sp = 2.75). ES is therefore 1.04. This effect size is

considered large 95, which corresponds to our expectation of the impact of D50 on
air leak rate. Using this parameter, we can plot the power of an eventual Phase II
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Figure 15

on RStudio74:

Power calculation PLUG-2 trial

Based on this calculation, 16 patients per group would lead to an adequately
powered study, which is similar to the previous calculation.
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It is not known if the duration of chest tube drainage will be normally distributed in
each group, and thus compared using two sample T test. If it is not, a
nonparametric test will have to be used (Mann-Whitney U test). Increase of 15%
of the sample size is recommended to maintain sufficient power if the sample
size was calculated with the assumption of a normally distributed primary
outcome when it was not97. Generally, endpoints in health care studies are more
likely to be positively skewed (and therefore not normal). In addition, to account
for a 10% loss of follow-up, further rise in the sample size is warranted. In
summary, a sample size of 20 patients per group is considered as satisfactory.

Intention to treat and per protocol analyses will be applied. Mann-Whitney U test
will be used to compare median DCTD between groups as mentioned above.
Chipatients with prolonged air leak (> 5 days) between groups. Secondary outcomes
will be evaluated using parametric and nonparametric statistical tests
accordingly. Univariate and multivariate logistical and linear analyses to assess
association between outcomes and baseline characteristics (sex, Charlson
Comorbidity Index, type of resection, surgical approach, smoking status, air leak
rate) will be conducted. An interim analysis assessing safety, efficacy, and
possibly to adjust the volume of D50 to 200 mL will be performed when 50% of
the sample size population is reached.
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7.4

EXPECTED RESULTS AND SIGNIFICANCE

We propose an achievable sample size of 40 patients (20 per group) that should
demonstrate a decrease in the DCTD with D50. We selected this endpoint as it is
an objective patient-oriented outcome. We assume chest tubes are painful and
patients do not like them. There has not been a validated instrument for QoL
after oncological lung resection surgery

this is the closest endpoint there is.

Based on our Phase I study, accrual could be completed in about 1 year if one
additional centre participates.

We anticipate that D50 will replace talc as our pleurodesis agent of choice and
become the new standard for sealing air leaks following lung resection surgery.
Should we be successful in mitigating post-operative air leaks in patients
undergoing lung resections, we will reduce their hospital length of stay. This
intervention should improve patient outcomes by shortening the duration that a
chest tube is required in the pleural space, minimizing post chest tube removal
pneumothoraces, lessen chest tube-related pain, decrease the risk of postoperative infections, and health care costs. Should this simple, inexpensive, and
novel therapy work to heal pulmonary air leaks, it will be a significant
advancement in overcoming this longSurgery.
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7.5

LIMITATIONS

Accrual of patients may be slowed down by the ongoing COVID-19 pandemic
and ORs shutdown. Additionally, accrual could be slow if thoracic surgeons are
reluctant to consent patients for this study.

It took 9 months to accrue 12 patients in the present study in a single center.
Involvement of at least another center will allow us to complete the study in a
reasonable time frame.

Given the fact that we already obtained Health Canada approval to run this
Phase I study, it is likely that we will be able to proceed with a Phase II study
from a Research Ethics Board perspective.

Funding could be granted via a London Regional Cancer Program (LRCP)
Catalyst grant as the patient population studied is mostly recovering from
oncological surgery, or an Academic Medical Organization of Southwestern
Ontario (AMOSO) grant.
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PROTOCOL SUMMARY
Title:

PLeurodesis Using hypertonic Glucose administration to
treat post-operative air leaks following lung resection
surgery (PLUG): Phase I trial.

Précis:

Patients with air leaks on postoperative day 2 following
lung surgery will be invited to participate in the study. The
precise definition of air leak is included in inclusion criteria.
Dextrose 50% (D50) will be injected sterilely into the chest
tube following the administration of 20 mL of 1% lidocaine.
Twenty-four hours after the intervention, if there is an air
leak cessation (defined elsewhere), chest tube removal
will be considered by the surgical team. If an air leak is still
present, no further intervention will be planned. The exact
time of cessation of air leak, time of chest tube removal,
date of discharge, and any adverse events will be
prospectively recorded. The volume of D50 administered
is incremental and will follow a rule-based escalation, 3+3
design: 3 patients will have a set dose, and if there are no
dose-limiting toxicities or less than 2 moderate toxicity, the
next group of 3 patients will go up one increment following
review from the study safety committee to insure the
acceptability of the treatment according to its side effects.
The safety committee will meet every 4 weeks to review
adverse events. The empiric increments will be 50 mL,
100 mL, 150 mL, and 200 mL. Therefore, a maximum of
12 patients will have to be enrolled.

Objectives:

The primary outcome is safety as defined by the lack of a
grade 3, 4, or 5 adverse events at any given D50 volume
according to the Common Terminology Criteria for
Adverse Events of the National Cancer Institute version
4.0. Secondary outcomes include the persistence of the
air leak at 24h, 48h and 72h following the intervention, the
pain score and point-of-care glucose measurement at 1h,
3h, 6h and 24h after the intervention, the pain level using
a visual analog scale at 1h, 3h, 6h, and 24h after
intervention, the output from the chest tube during the first
24h after the intervention, the length of hospital stay, the
duration of chest tube drainage, the need to discharge the
patient with a one-way valve, the need for an additional
chest tube insertion, the increase in supplemental oxygen
requirements, the air leak rate, and the post-operative
morbidity. In addition, patient analgesia consumption will
be monitored, including the type of analgesia and the
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route of administration until the earliest between discharge
day versus post-operative day 5. Also, the need for an
intervention to address hyperglycemia will be monitored,
including what type of intervention (insulin administration?)
and the length of intervention. All of the above outcomes
will be measured until post-operative day 5, except for
potential infectious complications which would be
measured until post-operative day 14. The recurrence of
an air leak at 60 days will also be monitored.

Population:

Total of 12 adult patients (18 years or older) following lung
resection surgery with an active air leak on post-operative
day 2 in London, Ontario.

Phase:

1

Sites:

1 Victoria Hospital, London Health Sciences Centre,
London, ON

Description of study agent: Dextrose monohydrate injection USP 50%
concentration (50 mg/mL). Volume of 50 mL, 100 mL, 150
mL, or 200 mL
Study duration:

Approximately 2 months

Participant duration:

Approximately 3 months

Clinical Trial Protocol

v2.05 20190711

viii

PLUG-1
Protocol MQRM711

Version 2.05
11 July 2019

SCHEMATIC OF STUDY DESIGN

Clinical Trial Protocol

v2.05 20190711

ix

PLUG-1
Protocol MQRM711
1

Version 2.05
11 July 2019

KEY ROLES

Richard Malthaner, MD MSc FRCSC FACS
Principal Investigator
Chair/Chief, Division of Thoracic Surgery
Director, Thoracic Surgery Research
Professor of Surgery, Epidemiology and Biostatistics
Schulich School of Medicine and Dentistry
Western University, Canada
Lawson Health Research Institute Scientist

Mehdi Qiabi, MD FRCSC
Co-investigator
Resident, Thoracic Surgery
Schulich School of Medicine and Dentistry
Western University, Canada

Deb Lewis, BSc CCRC
Research Coordinator, Thoracic Surgery
Program Administrator, Western University
London Health Sciences Centre, Victoria Hospital

Clinical Trial Protocol

v2.05 20190711

1

PLUG-1
Protocol MQRM711

Version 2.05
11 July 2019

2

INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC
RATIONALE

2.1

BACKGROUND INFORMATION

Pulmonary air leaks from unhealed lung tissue is one of the most common
complications after lung surgery. This adverse event leads to a delay in chest
tube removal, prolonged pain, increased infections, prolonged hospital stay, and
increased costs to the health care system 1. Different agents have been used to
heal air leaks by pleurodesis but the success and safety profile of these agents
has been variable. Instillation of a talc slurry into the pleural space is our current
preferred method in stopping air leaks after lung resection. This technique can
cause an acute lung injury and the long-term effects of talcosis remain a concern
to some practitioners and some patients 2,58,98. There has been recent interest in
the use of hypertonic glucose (D50) to create pleurodesis from encouraging
reports coming from Asia6 8,49. We have performed a pilot study using 180 mL of
50% hypertonic glucose instilled through the chest tube for the management of
post lobectomy air leak and the results were encouraging 9.
Summary of all data
The search was completed on April 16, 2019 using the terms (dextrose OR
glucose) AND pleurodesis on PubMed and Google Scholar. Abstracts,
articles,and their bibliographies were reviewed to find more studies.
Articles where the intervention was intrapleural administration of any volume of
hypertonic glucose were included. If the dextrose was administered
concomitantly with another agent (such as talc), the study was rejected.
A total of 18 studies were found, covering 275 patients (Table 1). The
concentration of Dextrose ranged from 20% to 50%. The volume of intrapleural
dextrose during initial administration ranged from 60 mL to 500 mL. The maximal
total volume administered was 1500 mL (3 times 500 mL over 3 days).
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n

Population

Chen34

2010 case series

China

Chung49

2008 cohort

South Korea

49 primary spontaneous pneumothorax

Tsukioka7

2013 cohort

Japan

20 secondary spontaneous pneumothorax

Hamada10

2017 case series

Japan

Peng50

2002 case series

China

Chee44

1992 case report

Singapore

Fujino6

2016 cohort

Japan

Takanashi53

2015 case report

Japan

Togo54

2016 case series

Japan

Tsukioka8

2013 case series

Albargawi9

5 post-esophagectomy

2 spontaneous pneumothorax
45 recurrent pneumothorax
1 spontaneous pneumothorax

Intervention

Adverse events

50% glucose + 0.1% lidocaine (volume?) through the
tube
thoracoscopic procedure (bleb
resection/bullectomy/electrocoagulation) +
instillation of dextrose 20% 200 cc
VATS bullectomy + mechanical abrasion + dextrose
50% (500 cc)

self resolving dyspnea

1- 200 mL of dextrose 50%
2- 400 mL of dextrose 50%
60-80 mL of Dextrose 50% through the tube

rate of fever 22% (dextrose group) vs 10% (no
dextrose group)
1 deatha 24 days after the surgery from a
pneumonia,1 prolonged air leak (15 days), 2
prolonged thoracic drainage, 1
transient elevation of blood sugar
2 deathsb

,

7/45 had mild pain

50 mL dextrose 50%

pulmonary edemac

46 35 post-lung resection patients with air leak
and 11 patients with pneumothorax and
prolonged air leak with a tube in place
1 spontaneous pneumothorax

200 mL of 50% glucose, between 1 and 3 doses, 7
patients had OK-432 after their 3rd dose for failure of
the glucose to work
50% glucose, 400 mL

mild transient hyperglycemia in 20/46 patients

Japan

29 14 pneumothorax, 11 post-lung resection air
leak, 4 malignant pleural effusion
13 spontaneous pneumothorax

200 mL of 50% glucose (2 patients had 100 mL for
« poor performance status »)
200 - 500 mL 50% glucose through the tube, they
often required more than one treatment

2016 cohort

Canada

10 post-lobectomy air leak

200 mL dextrose 50% with lidocaine, one or twice

Frick45

1990 case series

Germany

32 spontaneous pneumothorax

Sumitomo52

2017 case series

Japan

13 post-lung resection air leak

Kitagata55

2018 case report

Japan

1 leak post right lower lobectomy

thoracoscopic pleurodesis with electrocoagulation of
bullae, visceral/parietal pleurae cauterized, chemical
pleurodesis with dextrose 50%
200 mL glucose 50%, repeated as needed (2 patients
had pleurodesis twice)
glucose 50%

Yaginuma56

2016 case report

Japan

pleurodesis with glucose 50% and minocycline

none

Kajikawa57

2017 case series

Japan

1 spontaneous pneumothorax on mechanical
ventilation
5 spontaneous pneumothorax

pleurodesis with 200 mL glucose 50%

transient hyperglycemia

Wei99

2016 case report

China

1939 case report

US

diaphragm repaired, pleural effusion evacuated, and
pleurodesis performed with dextrose 50%
glucose 50% 50 mL, then 60% 67 mL

?

Hennell42

1 hydrothorax secondary to peritoneal dialysis
catheter
1 Chronic pneumothorax

ischemic colitis secondary to severe dehydratation
(1960 mL/4 hours), prerenal acute renal failure
Mild transient hyperglycemia, chest pain and fever
2 "bacterial pleuritis" (both of them required more
than 1 treatment, and they had their tube 25 and 35
days, treated with antibiotics only), 1 aspiration
pneumonia
mild increase in chest tube output, mild increase in
blood sugar
Horner syndrome (secondary to pleural cauterization)
none
none

none

Table 1. List of all studies. VATS: video-assisted thoracic surgery, POD: post-operative day. a,b,c cf description of the events in the text
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RATIONALE

Air leaks from unhealed lung tissue are one of the most common complications after
lung surgery including wedge resection, segmentectomy and lobectomy. Air leaks can
lead to a delay in chest tube removal, prolonged pain, increased infections, prolonged
hospital stay, and increased costs to the health care system 1. Different agents have
been used to heal air leaks by creating a pleurodesis (adhesions to obliterate the pleural
space between the visceral and parietal pleura). The success with these agents has
been variable and come with the cost of complications that have restricted their use the
post-operative period 2. There has been recent interest in the use of D50 to create
pleurodesis with encouraging reports coming mostly from Asia 6 8. We have performed a
pilot study using D50 instilled through the chest tube for the management of post
lobectomy air leak with encouraging results9. This preliminary study used strict inclusion
criteria of only lobectomy patients and excluded many other patients such as patients
with diabetes or any postoperative hyperglycemia that may benefit from this
intervention. Also, the optimal dose of D50 was chosen empirically and never clearly
defined by previous work. It has been reported that high doses of D50 was associated
to acute lung injury10. It is therefore critical that the optimal safe dose is clarified.
Objective: To define the most appropriate safe dose of D50 to heal air leaks in patients
that have undergone lung resection surgery (Phase I study).
Hypothesis: In patients with a postoperative air leak following lung resection, the
bedside administration of D50 into the pleural space on postoperative day 2 is safe
(Phase I trial).
We predict that D50 will be found safe because no severe adverse events occurred with
optimum dose found in the Phase I study. This will provide the motivation and data to
proceed with a formal Phase II study to assess the effectiveness of the chosen dosage
in reducing the length of stay and length of chest tube drainage, and then a Phase III
randomized clinical trial.
We anticipate that D50 will replace talc as our pleurodesis agent of choice and become
the new standard not only for sealing air leaks following lung resection surgery but also
achieving pleurodesis for chronic pleural effusions. Should we be successful in reducing
postoperative air leaks in patients undergoing lung resections, we will reduce their
hospital length of stay. This intervention should improve patient outcomes by shortening
the duration that a chest tube is required, reducing post chest tube removal
pneumothoraces, decrease chest tube related pain, decrease the risk of postoperative
infections, hospital length of stay, and health care costs. Should this simple,
inexpensive, and novel therapy work to heal pulmonary air leaks, it will be a significant
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2.3

POTENTIAL RISKS AND BENEFITS

2.3.1

KNOWN POTENTIAL RISKS

A literature review is summarized in the Table 1. In five papers 6,9,52,54,55, the population
studied were post-lung resection patients with air leak (70 patients). In these 70
subjects, reported adverse events were as follow:
mild transient hyperglycemia (n=26/70)
mild transient chest pain
mild transient fever
mild increase in chest tube output
In these 70 patients, reported adverse events were mild. This population is similar to the
population we plan to study. The concentration of dextrose was 50%. Except for one
study55 in which the data was not available, they all had administration of 200 mL,
repeated up to 2 other times for a total of 600 mL over 3 days. There was no infectious
complication.
In all 275 patients, infectious complications related to the intervention were rare. One
study7 where 20 patients underwent a bullectomy, mechanical abrasion and
administration of 500 mL of Dextrose 50% in the operating room had one case of
thoracic drainage and the volume of air leakage may contribute to the development of a
nother study8 where 13 patients had spontaneous pneumothorax
treated with a chest tube and then administration of between 200 to 500 mL of dextrose
50%, repeated up to a total of 3 times (500 mL administered 3 times over 3 days)
for a prolonged period of time (25 and 35 days), and they both had repeated
administration of 500 mL of dextrose 50% (one had a total of 2 doses and the other 3
doses). All these 3 patients were treated conservatively with antibiotics.
Ischemic colitis induced by dehydration was reported after the administration of 400 mL
of Dextrose 50% on a 97 years old gentleman to induce pleurodesis after a
spontaneous pneumothorax 53. This was treated conservatively with rehydration and
surgery was not required.
Chee44 reported a case of dextrose pneumonitis. The 51 years old male with chronic
obstructive airways disease complicated by cor pulmonale and hypercapnic respiratory
failure had a spontaneous pneumothorax. He had a prolonged air leak for 41 days.
Intrapleural instillation of 50 mL of Dextrose 50% was performed and the patient
experience cardiorespiratory collapse requiring cardiopulmonary resuscitation. It was
noted that copious amount of secretions was coming from the endotracheal tube,
positive for glucose by a dipstick. The patient recovered well after that event and the
leak stopped. It was postulated that osmotic pulmonary edema may have been caused
by the high tonicity of the dextrose 50%.
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Of the 275 patients who underwent intrapleural hypertonic dextrose administration for
pleurodesis, a total of 3 deaths were reported.
4- In Tsukioka7 paper, a 79 years old male with severe emphysema, unresectable
lung cancer who recently had chemotherapy, underwent a bullectomy,
mechanical abrasion of the pleura, and administration of 500 mL of dextrose 50%
in the pleural cavity. Twenty-four days after his surgery, he passed away from a
pneumonia. It is unclear whether his death is related to the administration of a
sclerosing agent.
5- In Hamada10 paper, a 72 years old male with a stage IV lung cancer and severe
emphysema, presented with spontaneous pneumothorax. He was first treated
with 5 rounds of OK-432 (sclerosing agent available in Japan to induce
pleurodesis), but it did not work and the leak was still present. Then, 4 rounds of
autologous blood and 200 mg of minocycline were injected into the pleural cavity
via the chest tube, again without success. Finally, 200 mL of dextrose 50% was
injected into the pleural space. The patient suffered from acute respiratory
distress syndrome and had to be intubated. He eventually died from progression
of respiratory failure. While there seems to be a temporal association, the
causality is uncertain.
6- In Hamada10 paper, a 84 years old male with idiopathic pulmonary fibrosis, on
home oxygen and hypercapnic respiratory failure developed a spontaneous
pneumothorax. A chest tube was inserted, and 400 mL of dextrose 50%
administered into the pleural space. Immediate pain and respiratory failure
occurred. It was recommended for the patient to be intubated, but the family
refused. The patient died 1 week later from progression of respiratory failure.
In the case of Patient 1, the death seems to be related to a nosocomial pneumonia and
not from the intervention. Patient 2 had multiple attempts at pleurodesis with various
agents (OK-432, blood, minocycline) before dextrose was tried. This is not the type of
intervention planned in the current proposed study. Patient 3 seemed to have an acute
reaction to dextrose 50%. The volume administered is twice the maximum dose we are
planning to use.
The potential safety concerns we will be ready to face are:
acute respiratory distress
dehydration
pain
hyperglycemia
fever
It is hypothesized that the value of the information gained by performing this study will
allow health care providers to have another option when comes the time to offer a
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patient chemical pleurodesis (instead of offering talc, thoracic surgeons or respirologists
will have the option of administering hypertonic glucose.
2.3.2

KNOWN POTENTIAL BENEFITS

After pulmonary resection, air leak is one of the most common complications arising
from lung parenchyma at sites of division of adhesions, fissure dissection or lung
retraction for exposure. A chest tube inserted at the end of the procedure will drain any
ongoing air-leak allowing the underlying lung to re-expand.
Patients who have an air leak on post-operative day 2 typically are typically offered
observation, hoping the air leak will seal by itself. However, previous work showed that
a significant number of patients who still leak on POD2 will have a prolonged air leak
(more than 5 days), and then will be typically offered one of 3 options:
1- waiting a longer period of time before removing the chest tube, with possibly
discharging the patient home with a small one way valve if the lung stays well inflated,
hoping the leak will have stopped at the next outpatient visit
2- injection of a sclerosing agent (such as talc) into the pleural space hoping the leak
will stop
3- reoperation, hoping we can stop the leak
It is known in the thoracic surgery literature that the longer a leak persists, the more
likely the patient may suffer from an infection of the pleural space. Other complications
such as catheter-related discomfort, arrhythmia or deep vein thrombosis could
potentially be attributed to prolonged length of stay.
Reports have shown some efficacy in inducing pleurodesis. Participants to the study will
therefore potentially be able to be discharged home sooner, have their chest tube
removed sooner (leading to pain relief), and because the leak would stop earlier, there
is a hypothetic benefit in reducing the risk of post-operative infectious complications 18.
In addition, the worldwide current standard of practice to treat post-operative air leaks is
typically to perform bedside chemical pleurodesis. A talc slurry is the most commonly
used agent. A 2016 systematic review from Cochrane 33 revealed that a wide range of
agents are used to induce pleurodesis, including tetracycline (antibiotic), doxycycline
(antibiotic), mepacrine (anti-malarial drug), bleomycine (chemotherapy agent),
doxorubicin (chemotherapy agent), proviodine (antiseptic agent), OK-432 (inactivated
preparation of Streptococcus pyogenes), C. parvum (bacteria), interferon
(immunomodulating agent), chlormethine (chemotherapy agent), mitoxantrone
(chemotherapy agent), and triethylenethiophosphoramide (chemotherapy agent). They
all have various risk of toxicity, and a simpler agent such as dextrose could possibly
provide similar efficacy with a better safety profile.
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OBJECTIVES AND PURPOSE

Objective: To define the most appropriate safe dose of D50 to heal air leaks in patients
that have undergone lung resection surgery (Phase I study).
Hypothesis: In patients with a postoperative air leak following lung resection, the
bedside administration of D50 into the pleural space on postoperative day 2 is safe
(Phase I trial).
4

STUDY DESIGN AND ENDPOINTS

4.1

DESCRIPTION OF THE STUDY DESIGN

In this single-arm, phase I, single-center trial, patients with air leak on postoperative day
2 following lung surgery will be invited to participate in the study. The precise definition
of air leak is found in 4.2.2. The solution to be used as pleurodesis agent will consist of
sterile 50% Glucose to be injected into the chest tube following the administration of 20
mL of 1% lidocaine. The glucose solution is manufactured and marketed by Pfizer
00037974) The agent comes in pre-filled 50 mL syringes (AnsyrTM II Syringe, product
code 07517001), 25 g/50 mL.. Twenty-four hours after the intervention, if there is an air
leak cessation (defined in 4.2.2), chest tube removal will be considered by the surgical
team. However, if an air leak is still present, no further intervention will be planned. The
exact time of cessation of air leak, time of chest tube removal, date of discharge, and
any adverse events will be prospectively recorded. The volume of D50 administered is
incremental and will follow a rule-based escalation, 3+3 design 63: 3 patients will have a
set dose, and if there are no dose-limiting toxicities (cf 6.1.7) or less than 2 moderate
toxicties, the next group of 3 patients will go up one increment following review from the
study safety committee to insure the acceptability of the treatment according to its side
effects. The safety committee will meet on a monthly basis to review adverse events.
The empiric increments will be 50 mL, 100 mL, 150 mL, and 200 mL. Therefore, a
maximum of 12 patients will have to be enrolled.
4.2

STUDY ENDPOINTS

4.2.1

PRIMARY ENDPOINT

The primary outcome of the Phase I study will be safety as defined by the lack of a
grade 3, 4, or 5 adverse event at any given D50 volume according to the CTCAE v4.0 64.
4.2.2

SECONDARY ENDPOINTS

Secondary outcomes include the persistence of the air leak at 24h, 48h and 72h
following the intervention, the pain score and point-of-care glucose measurement at
baseline, 1h, 3h, 6h and 24h after the intervention, the pain level using a visual analog
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scale at 1h, 3h, 6h, and 24h after intervention, the output from the chest tube during the
first 24h after the intervention, the length of hospital stay, the duration of chest tube
drainage, the need to discharge the patient with a one-way valve, the need for an
additional chest tube insertion, the increase in supplemental oxygen requirements, the
air leak rate, and the post-operative morbidity. In addition, patient analgesia
consumption will be monitored, including the type of analgesia and the route of
administration until the earliest between discharge day versus post-operative day 5.
Also, the need for an intervention to address hyperglycemia will be monitored, including
what type of intervention (insulin administration?) and the length of intervention. All of
the above outcomes will be measured until post-operative day 5, infectious adverse
events will be recorded until 2 weeks post-op. The recurrence of an air leak at 60 days
will also be monitored.

Definition of air leak
The presence of an air leak using the Medela Thopaz TM digital system is defined as an
air leak equal or more than 40 mL/min for at least 1 hour during the last 12 hours if the
tube is on suction, or equal or more than 20 mL/min for at least 1 hour during the last 12
hours if the tube is on gravity mode.
Definition of cessation of air leak
An air leak has stopped if there was no record of sustained air leak (1 hour or more) of
40 mL/min or more for the last 12 hours if the tube is on suction, or equal or more than
20 mL/min for at least 1 hour during the last 12 hours if the tube is on gravity mode.
5

STUDY ENROLLMENT AND WITHDRAWAL

5.1

PARTICIPANT INCLUSION CRITERIA

In order to be eligible to participate in this study, an individual must meet all of the
following criteria:
1.
2.
3.
4.
5.2

18 years old or older
Lung resection is a wedge, segmentectomy, lobectomy or bilobectomy
Procedure performed by video-assisted thoracic surgery, or by thoracocomy
Presence of an air leak on the digital draining system on POD#2
PARTICIPANT EXCLUSION CRITERIA

An individual who meets any of the following criteria will be excluded from participation
in this study:
1. Large air leak arbitrarily defined as more than 1000 mL/min
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2. Allergy to local anesthetics
3. Hemodynamic instability
4. Untreated coronary artery disease
5. Need for respiratory support
6. Any other early post-operative complication
7. Immunity disorder
8. Large fluid output arbitrarily defined as more than 500 mL in the last 12 hours
9. Inability to give consent
10. Fasting glucose 14 mmol/L the morning of the intervention (arbitrarily chosen cut-off
11. Endocrinology service not available to co-manage patients with either diabetes, or a
fasting blood glucose 7 mmol/L, or HbA1c > 6.5%
12. Postoperative evidence of an active thoracic (lung or pleura) infection with SIRS (2
or more of temperature > 38, heart rate > 90, respiratory rate > 20, WBC > 12)
5.3

STRATEGIES FOR RECRUITMENT AND RETENTION

On post-operative day 1, if the patient has an air leak as evaluated by the circle of care
(thoracic surgery residents), s/he will be approached to assess whether s/he would be
interested to participate in a study to treat air leaks. If the patient seems interested, the
PI, co-investigator or the research coordinator will obtain consent.
All lung resections in London, Ontario are performed in Victoria Hospital, and all the
members of the Division of Thoracic Surgery, along with residents/nurse practitioners
will be made aware of the existence of this study and the details.
5.4

PARTICIPANT WITHDRAWAL OR TERMINATION

5.4.1

REASONS FOR WITHDRAWAL OR TERMINATION

Participants are free to withdraw from participation in the study at any time upon
request. All data collected up until withdrawal of consent will be kept and analyzed, but
study if:
the participant meets an exclusion criterion (either newly developed or not
previously recognized) that precludes further study participation
if the patient meets criteria mentioned in sections 5.5 or 8.5

5.4.2

HANDLING OF PARTICIPANT WITHDRAWALS OR TERMINATION

In this Phase I trial, we aim to capture adverse events, serious adverse events, and
unanticipated problems. The intervention will happen only once and then the follow-up
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is short (a few days). It would be unlikely to have participants withdrawing from the
study or be terminated.
If the study is prematurely terminated, participants will not be replaced.
If the study is not prematurely terminated, but the participant voluntarily withdraws from
participation in the study, this subject will be replaced by approaching the next available
patient who would satisfy inclusion and exclusion criteria as outlined in sections 5.1 to
5.3.
5.5

PREMATURE TERMINATION OR SUSPENSION OF STUDY

The study will be stopped entirely due to safety concern if any grade 4 or 5 (death)
adverse events according to the Common Terminology Criteria for Adverse Events
(CTCAE) v 4.0 occurs, or if the patient is transferred to the intensive care unit (ICU) for
any condition thought to be secondary to the intervention, or if the patient experiences
pain (8/10 or more on visual analog scale) immediately after the intervention not
relieved by oral or subcutaneous analgesia.
6

STUDY AGENT

6.1

STUDY AGENT AND CONTROL DESCRIPTION

6.1.1

ACQUISITION

The study agent is manufactured and marketed by
filled 50 mL syringes
II Syringe, product code 07517001), 25 g/50 mL. It will be
acquired from the hospital pharmacy.
(AnsyrTM

6.1.2

FORMULATION, APPEARANCE, PACKAGING, AND LABELING

The agent comes in pre-filled 50 mL syringes (Ansyr TM II Syringe). The solution is clear.
Please refer to the product brochure.
6.1.3

PRODUCT STORAGE AND STABILITY

Product should be stored between 20 to 25°C. Protect from freezing and excessive
heat.
Parenteral drug products should be inspected visually for particulate matter and
discolouration prior to administration, whenever solution and container permit.
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Do not use unless solution is clear and container or seal intact. Discard if it contains a
precipitate. Single-use; discard unused portion.
Please refer to the product brochure.
6.1.4

PREPARATION

The drug comes in pre-filled syringe. There is no preparation needed. In cases of
volume superior to 50 mL (i.e. 100 mL, 150 mL or 200 mL), multiple syringes may have
to be used.
6.1.5

DOSING AND ADMINISTRATION

The volume of Dextrose 50% administered is incremental and will follow a rule-based
escalation, 3+3 design: 3 patients will have a set dose, and if there are no dose-limiting
toxicities or less than 2 moderate toxicities (cf. 6.1.7), the next group of 3 patients will go
up one increment following review from the study safety committee to insure the
acceptability of the treatment according to its side effects. The safety committee will
meet on a monthly basis to review adverse events. The empiric increments will be 50
mL, 100 mL, 150 mL, and 200 mL. Therefore, a maximum of 12 patients will have to be
enrolled.
6.1.6

ROUTE OF ADMINISTRATION

The route of administration will be intra-pleural through the chest tube already in place.
The chest tube tubing will be disinfected, and then the solution injected into the tube.
The tubing is kept elevated 50 cm above the chest of the patient in order to promote
movement of the solution into the chest, and not into the digital drain device. The tube
will not be clamped as there is an air leak, and clamping the tube may induce a tension
pneumothorax (lung collapse).
6.1.7

STARTING DOSE AND DOSE ESCALATION SCHEDULE

Each participant will receive one dose only. The volume given will not be the same for
all participants. We will start with 3 patients receiving 50 mL, then 3 other patients
receiving each 100 mL, and so forth until reaching 200 mL after a total of 12
participants.
Dose limiting toxicities include any grade 4 or grade 5 (death) adverse events according
to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.0., in addition of
the following:
1. Transfer to the ICU for any cause presumed to be related to the intervention
2. Pain score equal or more than 8/10 in visual analog scale not relieved by oral or
subcutaneous analgesia
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Moderate toxicities include all grade 3 toxicities presumed to be related to the
intervention, in addition of the following:
1. Very high chest tube output, arbitrarily defined as > 1 L/12 hours
6.1.8

DOSE ADJUSTMENTS/MODIFICATIONS/DELAYS

Adjustments or modifications of dose is not anticipated.
6.1.9 DURATION OF THERAPY
Data will be recorded and tracked until post-operative day 5 or until discharge. A followup visit will happen at post-operative day 14 to monitor for infectious adverse events.
6.1.10 TRACKING OF DOSE
The dose is administered by the circle of care (thoracic surgery residents). It will also be
listed in the MAR (Medication Administration Record).
6.2

STUDY AGENT ACCOUNTABILITY PROCEDURES

The study agent will be sent to the Thoracic Surgery Ward as for any other drug. Upon
reception to the ward, it will be administered.
7

STUDY PROCEDURES AND SCHEDULE

7.1

STUDY PROCEDURES/EVALUATIONS

7.1.1

STUDY SPECIFIC PROCEDURES

If a participant is enrolled into this trial, s/he will require the following study procedures:
Point of care glycemia evaluation before the intervention, 1 hour after the
intervention, 3 hours after the intervention, 6 hours after the intervention, and 24
hours after the intervention
Should the glycemia rises above 11 mmol/L, co-management from an endocrinologist
and monitoring will be requested.
7.1.2

STANDARD OF CARE STUDY PROCEDURES

If a participant is enrolled into this trial, s/he will not require any other standard of care
procedure.
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7.2

LABORATORY PROCEDURES/EVALUATIONS

7.2.1

CLINICAL LABORATORY EVALUATIONS

The only laboratory evaluation required as part of this study is point-of-care glycemia.
7.2.2

OTHER ASSAYS OR PROCEDURES

N/A
7.2.3

SPECIMEN PREPARATION, HANDLING, AND STORAGE

N/A
7.2.4

SPECIMEN SHIPMENT

N/A
7.3

STUDY SCHEDULE

7.3.1

SCREENING

On post-operative day 1, if the patient has an air leak as evaluated by the circle of care
(thoracic surgery residents), s/he will be approached to assess whether s/he would be
interested to participate in a study to treat air leaks. If the patient seems interested, the
PI, co-investigator or the research coordinator will obtain consent.
POD#1
During morning rounds, the thoracic surgery residents assess whether there is
an active air leak or not
The circle of care will evaluate all inclusion and exclusion criteria, and, if
appropriate, will approach the patient to enquire if he would be interested in
participating in a study to treat post-operative air leaks
if the patient is interested, either the PI, a co-investigator or the study coordinator
will approach the patient, will explain the study and answer questions
7.3.2

ENROLLMENT/BASELINE

POD#2
If there is still an air leak during morning rounds, informed consent will be
obtained from the investigators if the patient is still interested with pursuing with
the trial
Clinical Trial Protocol

v2.05 20190711

14

PLUG-1
Protocol MQRM711

Version 2.05
11 July 2019

a baseline point-of-care glycemia will be performed at that time
7.3.3

FOLLOW-UP

All participants are hospitalized. They are followed up at least twice daily if inpatients.
All the outcomes are recorded until post-operative day 5 (or 72 hours after the
intervention), with the exception of infectious adverse events that can arise on a
delayed fashion. Patients will therefore be evaluated on POD#14 for that reason in an
outpatient setting (Thoracic Surgery clinic).
7.3.4

FINAL STUDY VISIT

The final study visit will be POD#14 (+/- 2 days to accommodate for statutory
holidays/weekends). Adverse events will be recorded.
7.3.5

EARLY TERMINATION VISIT

Evaluation of adverse events are performed if there is an early termination visit
(although unlikely).
7.3.6

UNSCHEDULED VISIT

The patients are instructed prior to discharge to let the Thoracic Surgery team know if
any adverse event occur. They are given instructions as to where/who to call during
weekdays hours and after-hours.
7.3.7

SCHEDULE OF EVENTS TABLE
Surgery

POD#1
POD#2
(screening)

Informed
consent
Administration
of D50
Adverse
events
evaluation

7.4

Discharge
from
hospital

POD#14
(final
study
visit)

X

X

X
X
X

CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES

N/A
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JUSTIFICATION FOR SENSITIVE PROCEDURES

N/A
7.5.1

PRECAUTIONARY MEDICATIONS, TREATMENTS, AND PROCEDURES

N/A
7.6

PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES

N/A
7.7

PROPHYLACTIC MEDICATIONS, TREATMENTS, AND PROCEDURES

Intrapleural lidocaïne 1%, 20 mL will be administered before hypertonic dextrose
administration
7.8

RESCUE MEDICATIONS, TREATMENTS, AND PROCEDURES

Pain, if any, will be managed as part of our standard post-operative order set
(analgesics).
Fever, if any, will be investigated. Fever, defined as an oral temperature equal or
superior to 38 degrees Celsius, will require performance of blood and pleural fluid
cultures. Acetaminophen administration will be avoided in order to not mask an
underlying infection. Acetaminophen will be administered only if absolutely necessary.
The reason for administration, the start time and date, the stop time and date, and the
total dose of acetaminophen administered will be recorded.
Hyperglycemia, if any, will be managed as part of our standard post-operative order set
(insulin scale if needed).
Desaturation, if any, will be managed as part of our standard post-operative order set
(supplemental oxygen).
If the air leak fails to heal despite dextrose administration, the study participant will not
be receiving more dextrose. It will be up to the Most Responsible Physician to use
his/her clinical judgement and perform one of these 3 options:
1. inject another intra-pleural agent such as talc (agent currently used in clinical
practice)
2. wait a few more days, and possibly discharge the patient home with a tube still in
place connected to a one-way valve
3. on very rare circumstances, patients may have to be re-operated to surgically
address the leak
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PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE

N/A
8

ASSESSMENT OF SAFETY

8.1

SPECIFICATION OF SAFETY PARAMETERS

8.1.1

DEFINITION OF ADVERSE EVENTS (AE)

Adverse event means any untoward medical occurrence associated with the use of an
intervention in humans, whether or not considered intervention-related (21 CFR 312.32
(a)).
8.1.2

DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)

Serious adverse event or serious suspected adverse reaction. An AE or suspected
adverse reaction is considered "serious" if, in the view of either the investigator or
sponsor, it results in any of the following outcomes: death, a life-threatening adverse
event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or
significant incapacity or substantial disruption of the ability to conduct normal life
functions, or a congenital anomaly/birth defect. Important medical events that may not
result in death, be life-threatening, or require hospitalization may be considered serious
when, based upon appropriate medical judgment, they may jeopardize the patient or
subject and may require medical or surgical intervention to prevent one of the outcomes
listed in this definition. Examples of such medical events include allergic bronchospasm
requiring intensive treatment in an emergency room or at home, blood dyscrasias or
convulsions that do not result in inpatient hospitalization, or the development of drug
dependency or drug abuse.
8.1.3

DEFINITION OF UNANTICIPATED PROBLEMS (UP)

OHRP considers unanticipated problems involving risks to participants or others to
include, in general, any incident, experience, or outcome that meets all of the following
criteria:
Unexpected in terms of nature, severity, or frequency given (a) the research
procedures that are described in the protocol-related documents, such as the
IRB-approved research protocol and informed consent document; and (b) the
characteristics of the participant population being studied;
Related or possibly related to partici
means there is a reasonable possibility that the incident, experience, or outcome
may have been caused by the procedures involved in the research); and
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Suggests that the research places participants or others at a greater risk of harm
(including physical, psychological, economic, or social harm) than was previously
known or recognized.
This study will use the OHRP definition of UP.
8.2

CLASSIFICATION OF AN ADVERSE EVENT

8.2.1

SEVERITY OF EVENT

For AEs not included in the protocol defined grading system, the following guidelines
will be used to describe severity.
Mild

Events require minimal or no treatment and do not interfere with the

Moderate Events result in a low level of inconvenience or concern with the
therapeutic measures. Moderate events may cause some interference with
functioning.
Severe
systemic drug therapy or other treatment. Severe events are usually potentially
life-threatening or incapacitating.
8.2.2

RELATIONSHIP TO STUDY AGENT

For all collected AEs, the clinician who examines and evaluates the participant will
poral relationship and his/her clinical
judgment. The degree of certainty about causality will be graded using the categories
below.
Definitely Related There is clear evidence to suggest a causal relationship,
and other possible contributing factors can be ruled out. The clinical event,
including an abnormal laboratory test result, occurs in a plausible time
relationship to drug administration and cannot be explained by concurrent
disease or other drugs or chemicals. The response to withdrawal of the drug
(dechallenge) should be clinically plausible. The event must be pharmacologically
or phenomenologically definitive, with use of a satisfactory rechallenge procedure
if necessary.
Probably Related There is evidence to suggest a causal relationship, and the
influence of other factors is unlikely. The clinical event, including an abnormal
laboratory test result, occurs within a reasonable time after administration of the
drug, is unlikely to be attributed to concurrent disease or other drugs or
chemicals, and follows a clinically reasonable response on withdrawal
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(dechallenge). Rechallenge information is not required to fulfill this definition.
Possibly Related There is some evidence to suggest a causal relationship
(e.g., the event occurred within a reasonable time after administration of the trial
medication). However, other factors may have contributed to the event (e.g., the
n, other concomitant events). Although an AE may

Unlikely to be related A clinical event, including an abnormal laboratory test
result, whose temporal relationship to drug administration makes a causal
relationship improbable (e.g., the event did not occur within a reasonable time
after administration of the trial medication) and in which other drugs or chemicals
clinical condition, other concomitant treatments).
Not Related The AE is completely independent of study drug administration,
and/or evidence exists that the event is definitely related to another etiology.
There must be an alternative, definitive etiology documented by the clinician.
8.2.3

EXPECTEDNESS

An AE will be considered unexpected if the nature, severity, or frequency of the event is
not consistent with the risk information previously described for the study agent. For
example, it is expected for intrapleural hypertonic glucose to produce some degree of
chest discomfort, low grade fever, and sometimes self-resolving dyspnea.
8.3

TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND
FOLLOW-UP

The occurrence of an AE or SAE may come to the attention of study personnel during
study visits and interviews of a study participant presenting for medical care, or upon
review by a study monitor.
All AEs including local and systemic reactions not meeting the criteria for SAEs will be
captured on the appropriate data report form. Information to be collected includes event
, relationship to study
product (assessed only by those with the training and authority to make a diagnosis),
and time of resolution/stabilization of the event. All AEs occurring while on study must
be documented appropriately regardless of relationship. All AEs will be followed to
adequate resolution.
Any medical condition that is present at the time that the participant is screened will be
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condition deteriorates at any time during the study, it will be recorded as an AE. UPs will
be recorded in the data collection system throughout the study.
Changes in the severity of an AE will be documented to allow an assessment of the
duration of the event at each level of severity to be performed. AEs characterized as
intermittent require documentation of onset and duration of each episode.
The PI will record all reportable events with start dates occurring any time after informed
consent is obtained until 7 (for non-serious AEs) or 60 days (for SAEs) after the last day
of study participation. At each study visit, the investigator will inquire about the
occurrence of AE/SAEs since the last visit. Events will be followed for outcome
information until resolution or stabilization.
8.4

REPORTING PROCEDURES

8.4.1

ADVERSE EVENT REPORTING

Study adverse events will be logged into the institutional data collection program
(REDCap). They will be disclosed to the Data Safety Monitoring Board on a monthly
basis.
8.4.2

SERIOUS ADVERSE EVENT REPORTING

The study clinician will complete a SAE Form within the following timelines:
All deaths and immediately life-threatening events, whether related or unrelated,
will be recorded on the SAE Form and submitted to the study sponsor and DSMB
within 24 hours of site awareness. See Section 1, Key Roles for contact
information.
Other SAEs regardless of relationship, will be submitted to the study sponsor and
DSMB within 72 hours of site awareness.
All SAEs will be followed until satisfactory resolution or until the site investigator deems
the event to be chronic or the adherence to be stable. Other supporting documentation
of the event may be requested by the study sponsor and should be provided as soon as
possible.
The study sponsor will be responsible for notifying Health Canada of any unexpected
fatal or life-threatening suspected adverse reaction as soon as possible but in no case
later than 7 calendar days after the sponsor's initial receipt of the information.
8.4.3

UNANTICIPATED PROBLEM REPORTING

Incidents or events that meet the OHRP criteria for UPs require the creation and
comple
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to their IRB and to the study sponsor and DSMB. The UP report will include the
following information:
ame, and the
IRB project number;
A detailed description of the event, incident, experience, or outcome;
An explanation of the basis for determining that the event, incident, experience,
or outcome represents an UP;
A description of any changes to the protocol or other corrective actions that have
been taken or are proposed in response to the UP.
To satisfy the requirement for prompt reporting, UPs will be reported using the following
timeline:
UPs that are SAEs will be reported to the IRB and to the study sponsor and
DSMB within 72 hours of the investigator becoming aware of the event.
Any other UP will be reported to the IRB, to the study sponsor and to the DSMB
within 7 days of the investigator becoming aware of the problem.
All UPs should be reported to appropriate institutional officials (as required by an
he supporting agency head (or
problem from the investigator.
8.4.4

EVENTS OF SPECIAL INTEREST

N/A
8.4.5

REPORTING OF PREGNANCY

N/A
8.5

STUDY HALTING RULES

Administration of study agent will be halted if on a single patient 2 grade 3 AEs
grade 4 or grade 5 (SAE) is reported. The Data Coordinating Center will notify the study
sponsor and investigators immediately and enrollment screens will stop accepting new
study participants. The study sponsor will inform the DSMB members within 24 hours of
this occurrence and will provide the DSMB with AE listing reports. The DSMB will
convene an ad hoc meeting by teleconference or in writing as soon as possible. The
DSMB will provide recommendations for proceeding with the study to the study
sponsor/Health Canada. The study sponsor will inform Health Canada of the temporary
halt and the disposition of the study.

Clinical Trial Protocol

v2.05 20190711

21

PLUG-1
Protocol MQRM711

Version 2.05
11 July 2019

8.6
SAFETY OVERSIGHT
Safety oversight will be under the direction of a DSMB composed of individuals with the
appropriate expertise, including lung and pleural physiology. Such individuals would be
physicians specialized in thoracic surgery, anesthesiology, respirology and
endocrinology. The DSMB will be independent from the study investigators. The DSMB
will meet at least monthly to assess safety data on the study. The first meeting will take
place before the first patient is enrolled. The DMSB will operate under the rules of an
approved charter that will be written and reviewed at the organizational meeting of the
DSMB. At this time, each data element that the DSMB needs to assess will be clearly
defined. The DSMB will provide its input to the principal investigator and co-investigator.
9
CLINICAL MONITORING
Clinical site monitoring is conducted to ensure that the rights and well-being of human
subjects are protected, that the reported trial data are accurate, complete, and
verifiable, and that the conduct of the trial is in compliance with the currently approved
protocol/amendment(s), and with applicable regulatory requirement(s).
One of the DSMB member will conduct a single, on-site, random monitoring
evaluation
Independent audits will not be conducted
Each clinical site will perform internal quality management of study conduct, data
collection, documentation and completion. An individualized quality management
plan wi
10

STATISTICAL CONSIDERATIONS

10.1

STATISTICAL AND ANALYTICAL PLANS

There will not be a formal statistical and analytical plan as our data will be mostly
descriptive in nature.
10.2

STATISTICAL HYPOTHESES

N/A
10.3

ANALYSIS DATASETS

N/A
10.4

DESCRIPTION OF STATISTICAL METHODS

10.4.1 GENERAL APPROACH
Our data will be mostly descriptive in nature. Data will be presented using percentages,
means (with standard deviations), median, range.
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10.4.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)
We do not anticipate any missing data. The data will be descriptive.
10.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S)
We do not anticipate any missing data. The data will be descriptive. Cf Section 10.4.11,
Exploratory Analyses.
10.4.4 SAFETY ANALYSES
The adverse events are graded using the CTCAE v.4.0. Information reported about
each AE are:
start time and date
stop time and date
severity
relationship
duration
AEs will be PI reported.
All grade 4 or grade 5 AEs are considered SAEs.
10.4.5 ADHERENCE AND RETENTION ANALYSES
N/A
10.4.6 BASELINE DESCRIPTIVE STATISTICS
Planned descriptive statistics include means and rate for demographics (age, gender,
comorbidities), ASA, conversion to thoracotomy, VATS/thoracotomy, type of lung
resection, presence of an air leak pre-op, mean glycemia increase over time, mean pain
increase over time, rate of resolution of air leak 24 hours, 48 hours and 72 hours after
the intervention, mean length of stay, mean chest tube output over 24 hours after the
intervention, mean duration of chest tube drainage, rate of patients needing to be
discharged on a one-way valve, rate of patients requiring insertion of another tube, need
for an increase in oxygen requirements after the intervention, rate of patients being
discharged with home oxygen, mean air leak rate 24 hours, 48 hours, and 72 hours
post-intervention.
10.4.7 PLANNED INTERIM ANALYSES
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SAFETY REVIEW

Please refer to Section 5.5, Premature Termination or Suspension of Study, and to
Section 8.5 Study Halting Rules.
No statistical analyses will be required for safety review.
10.4.7.2

EFFICACY REVIEW

N/A
10.4.8 ADDITIONAL SUB-GROUP ANALYSES
Because of the relatively small sample size, no sub-group analyses will be performed.
10.4.9 MULTIPLE COMPARISON/MULTIPLICITY
N/A
10.4.10 TABULATION OF INDIVIDUAL RESPONSE DATA
N/A
10.4.11 EXPLORATORY ANALYSES
If dramatic absolute differences are noted between different volumes of D50, we may
perform exploratory analyses (comparison between mean chest tube output at 24 hours
for instance between participants who received 50 mL versus 200 mL).
10.5

SAMPLE SIZE

For this phase I trial, we did not calculate a simple size as we will use a rule-based
escalation, 3+3 design 63. We will have 3 patients receiving each one administration of
the following volume of D50: 50 mL, 100 mL, 150 mL, 200 mL. We will require a total of
12 patients.
10.6

MEASURES TO MINIMIZE BIAS

10.6.1 ENROLLEMENT/RANDOMIZATION/MASKING PROCEDURES
The research coordinator will obtain consent and our nurse practitioner or physician
assistant will administer the dextrose. Assessment of adverse events will be performed
by the residents working in the thoracic surgery team and be logged in an institutional
secured database (REDCap). These residents are not investigators. The investigators
will therefore be blinded, thus reducing potential bias.
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Ultimately, we are planning to perform a Phase III which would be blinded to avoid
observer bias.
We will reduce selection bias by considering everyone for the study and approaching
them to participate.
10.6.2 EVALUATION OF SUCCESS OF BLINDING
We will ask members of the team if they knew what dose if any the patient received.
10.6.3 BREAKING THE STUDY BLIND/PARTICIPANT CODE
N/A
11

SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS

Data collected pertaining to the study will be stored on our institutional database
(REDCap), approved by Lawson Health Research Institute.
The principal investigator, co-investigators, research coordinator, Western University
Health Sciences Research Ethics Board, and Lawson Quality Assurance and Education
Program will have access to this data.
12

QUALITY ASSURANCE AND QUALITY CONTROL

Quality control procedures will be implemented beginning with the data entry system
and data quality control checks that will be run on the database will be generated. Any
missing data or data anomalies will be communicated for clarification/resolution.
The monitors will verify that the clinical trial is conducted and data are generated,
documented (recorded), and reported in compliance with the protocol.
The investigational site will provide direct access to all trial related sites, source
data/documents, and reports for the purpose of monitoring and auditing by the sponsor,
and inspection by local and regulatory authorities.
13

ETHICS/PROTECTION OF HUMAN SUBJECTS

13.1

ETHICAL STANDARD

The investigator will ensure that this study is conducted in full conformity with
Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part
46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.
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INSTITUTIONAL REVIEW BOARD

The protocol, informed consent form(s), recruitment materials, and all participant
materials will be submitted to the IRB for review and approval. Approval of both the
protocol and the consent form must be obtained before any participant is enrolled. Any
amendment to the protocol will require review and approval by the IRB before the
changes are implemented to the study. All changes to the consent form will be IRB
approved; a determination will be made regarding whether previously consented
participants need to be re-consented.
13.3

INFORMED CONSENT PROCESS

13.3.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS
PROVIDED TO PARTICIPANTS
Consent forms describing in detail the study agent, study procedures, and risks are
given to the participant and written documentation of informed consent is required prior
to starting intervention/administering study product. The following consent materials are
submitted with this protocol:
Letter of information & Consent
13.3.2 CONSENT PROCEDURES AND DOCUMENTATION
Informed consent is a process that is initiated prior to the
Extensive discussion of risks and possible benefits of participation will be provided to
the participants and their families. Consent forms will be IRB-approved and the
participant will be asked to read and review the document. The investigator will explain
the research study to the participant and answer any questions that may arise. All
participants will receive a verbal explanation in terms suited to their comprehension of
the purposes, procedures, and potential risks of the study and of their rights as research
participants. Participants will have the opportunity to carefully review the written consent
form and ask questions prior to signing. The participants should have the opportunity to
discuss the study with their surrogates or think about it prior to agreeing to participate.
The participant will sign the informed consent document prior to any procedures being
done specifically for the study. The participants may withdraw consent at any time
throughout the course of the trial. A copy of the informed consent document will be
given to the participants for their records. The rights and welfare of the participants will
be protected by emphasizing to them that the quality of their medical care will not be
adversely affected if they decline to participate in this study.
13.4

PARTICIPANT AND DATA CONFIDENTIALITY

Participant confidentiality is strictly held in trust by the participating investigators, their
staff, and the sponsor. This confidentiality is extended to cover the clinical information
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relating to participants. Therefore, the study protocol, documentation, data, and all other
information generated will be held in strict confidence. No information concerning the
study or the data will be released to any unauthorized third party without prior written
approval of the sponsor.
The study monitor, other authorized representatives of the sponsor, representatives of
the IRB may inspect all documents and records required to be maintained by the
investigator, including but not limited to, medical records (hospital) and pharmacy
records for the participants in this study. The clinical study site will permit access to
such records.
The study partici
internal use during the study. At the end of the study, all records will continue to be kept
in a secure location for as long a period as dictated by local IRB and Institutional
regulations. A master linking log with identifiers will be stored separately from the study
data.
Study participant research data, which is for purposes of statistical analysis and
scientific reporting, will be kept at the study center. Individual participants and their
research data will be identified by a unique study identification number. The study data
entry and study management systems used by the clinical site and by research staff will
be secured and password protected. At the end of the study, all study databases will be
de-identified and archived.
13.4.1 RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENTS OR DATA
Storage: Access to stored data will be limited using access to selected
individuals and password protected. Data will be stored using codes assigned by
the investigators. Data will be kept in password-protected institutional database.
Only investigators will have access to the data.
Data will be tracked using by logging who electronically access them
o Disposition at the completion of the study: All stored consent forms will be
13.5

FUTURE USE OF STORED SPECIMENS

N/A
14

DATA HANDLING AND RECORD KEEPING

14.1

DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES

Data collection is the responsibility of the clinical trial staff at the site under the
supervision of the site PI. The investigator is responsible for ensuring the accuracy,
completeness, legibility, and timeliness of the data reported.
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All source documents should be completed in a neat, legible manner to ensure accurate
interpretation of data. Black ink is required to ensure clarity of reproduced copies. When
making changes or corrections the original entry will be crossed out with a single line,
and initialed and date of the change will be recorded.
Clinical data (including AEs, concomitant medications, and expected adverse reactions
data) and clinical laboratory data will be entered into REDCap, a 21 CFR Part 11compliant data capture system. The data system includes password protection and
internal quality checks, such as automatic range checks, to identify data that appear
inconsistent, incomplete, or inaccurate.
14.2

STUDY RECORDS RETENTION

Study documents should be retained for a minimum of 25 years. No records will be
destroyed without the written consent of the sponsor, if applicable. It is the responsibility
of the sponsor to inform the investigator when these documents no longer need to be
retained.
14.3

PROTOCOL DEVIATIONS

A protocol deviation is any noncompliance with the clinical trial protocol. The
noncompliance may be either on the part of the participant, the investigator, or the study
site staff. As a result of deviations, corrective actions are to be developed by the site
and implemented promptly.
It is the responsibility of the site to use continuous vigilance to identify and report
deviations within 7 working days of identification of the protocol deviation, or within 7
working days of the scheduled protocol-required activity. All deviations must be reported
to Health Canada. Protocol deviations must be sent to the local IRB per their guidelines.
The site PI/study staff is responsible for knowing and adhering to their IRB
requirements.
14.4

PUBLICATION AND DATA SHARING POLICY

The International Committee of Medical Journal Editors (ICMJE) member journals have
adopted a clinical trials registration policy as a condition for publication. The ICMJE
defines a clinical trial as any research project that prospectively assigns human subjects
to intervention or concurrent comparison or control groups to study the cause-and-effect
relationship between a medical intervention and a health outcome. Medical
interventions include drugs, surgical procedures, devices, behavioral treatments,
process-of-care changes, and the like. Health outcomes include any biomedical or
health-related measures obtained in patients or participants, including pharmacokinetic
measures and adverse events. The ICMJE policy requires that all clinical trials be
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the
National Library of Medicine. Other biomedical journals are considering adopting similar
policies. The ICMJE does not review specific studies to determine whether registration
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is necessary; instead, the committee recommends that researchers who have questions
about the need to register err on the side of registration or consult the editorial office of
the journal in which they wish to publish.
15

STUDY ADMINISTRATION

15.1

STUDY LEADERSHIP

The Study Team will govern the conduct of the study. The Study Team will be
composed of the principal investigator, co-investigator and research coordinator.
16

CONFLICT OF INTEREST POLICY

The independence of this study from any actual or perceived influence, such as by the
pharmaceutical industry, is critical. Therefore, any actual conflict of interest of persons
who have a role in the design, conduct, analysis, publication, or any aspect of this trial
will be disclosed and managed. Furthermore, persons who have a perceived conflict of
interest will be required to have such conflicts managed in a way that is appropriate to
their participation in the trial. The study leadership has established policies and
procedures for all study group members to disclose all conflicts of interest and will
establish a mechanism for the management of all reported dualities of interest.
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Appendix G
Letter of Information & Consent
Project Title:

PLeurodesis Using hypertonic Glucose administration to treat
post-operative air leaks following lung resection surgery
(PLUG): Phase I trial.

Principal Investigator: Richard Malthaner, MD MSc FRCSC FACS
Research Director, Division of Thoracic Surgery
London Health Sciences Centre

Co-Investigators:

Mehdi Qiabi, MD FRCSC

Funded by:

UWO Internal Surgery

Internal Research Fund

Introduction:
invited to participate in a research study. You are being asked to participate because you
had a lung resection, and you are experiencing an air leak following your surgery. Before
you decide to participate, it is important for you to understand why this study is being
done what it will involve. Please take time to read the following information carefully
and discuss it with your family and friends and/or your family doctor if you wish. There
may be words of statements that you do not understand. Ask your study doctor or staff
to explain anything that is not clear or if you would like more information. Take time to
decide whether or not you wish to take part.
Before agreeing to participate in this study, it is important you know about the study. This
document describes the purpose, procedures, benefits, discomforts and risks associated
with this study, as well as your rights if you decide to participate in this study.
Purpose of Study:
Many patients experience air leaks after having a lung resection. This may cause you to
stay in the hospital for longer while this leak stops.
This clinical study will evaluate the feasibility and effectiveness of using a concentrated
glucose (sugar) solution injected into the space between your chest wall and your lungs,
to stop the leak.
Number of Participants:
Version 2019-09-05
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A total of 12 patients will be recruited.
Participation Eligibility:
You are eligible for the study if you have an air leak following your lung resection. That
air leak needs to be persistent for 2 days after your surgery. Note that you will only be
included if you have given your written consent to partake in the study.
Voluntary Participation:
Participation in this study is voluntary. You may refuse or agree to participate in the study.
You may withdraw from the study at any moment without any effect on your future care.
If you decide to withdraw from the study, the information that was collected before you
leave the study will still be used to help answer the research question. No new information
will be collected without your permission.
If you are not interested in participating in this study:
The standard of care is to wait until the leak stops on its own. It may take several days to
several weeks. Sometimes, we let patients go home with their chest tube still in place
attached to a one-way valve, and we reevaluate them in the clinic on a weekly basis.
Unfortunately, there are patients whose leak does not heal on its own. It is hard to predict
the duration of an air leak. In the case of a persistent air leak that does not heal on its
own, we normally inject a product through the tube going into the chest called talc to
create an inflammatory reaction and hope that it will stop the air leak. The longer the
duration of air leak, the higher the risk of infection. It is therefore hoped that the leak is
stopped as soon as possible. Rarely, patients may require a second surgery to address
and stop the air leak.
Goal of the study:
The research procedure offered to you is to inject a solution with high concentration of
sugar into the chest tube 2 days after the surgery if there is an air leak, hoping that the
leak stops quickly. We are therefore offering you an intervention sooner than we usually
would have. This intervention may or may not work.
You may choose not to participate in this study. This requires to keep the chest tube until
the leak stops.
Your study doctor can tell you more about your condition and the possible benefits of the
available treatments.
Be reassured that should you decide to refuse to participate in this study, the care you
will receive will be unaffected.
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Study Procedure:
If you choose to take part in this study, between 50 millilitres and 200 millilitres of a
solution of 50% glucose will be injected into your pleural space (the space between your
chest wall and your lungs) the second day after the surgery. This is done after injecting a
local anesthetic to numb your chest cavity (lidocaine). The injection will be administered
through your chest tube, which is already in place. There will be no injection of talc.
Some studies have already shown that a volume between 180 milliliters and 200 milliliters
seem to be effective and appears safe. However, these volumes were chosen arbitrarily.
The aim of this study is to be confident that the dose administered to patients is safe.
Each participant will receive only one injection of glucose at a defined volume. We will
start with a smaller amount (50 milliliters), and an independent group of physicians will
analyze the data and potential associated adverse events. They have a list of criteria. If
the dose is considered safe, we will increase the volume to 100 milliliters for the next
group of participants. The same process will repeat until we reach a maximum volume of
200 milliliters.
If you choose to take part in this study, you will be followed by a researcher who will
monitor you for the duration of your air leak, the duration of chest drainage, the length of
hospitalization, and the occurrence of complications or discomfort.
Potential benefits associated with participation in this study:
If you agree to take part in this study, there may or may not be direct medical benefit to
you. Your hospital stay and how long you require a chest tube may be reduced by this
treatment. It may also prevent further air leak or lung collapse, decrease chest tube pain,
and decrease post-operative complications.
Potential risks associated with participation in this study:
If you agree to participate in this trial, you may be at risk of potential side effects. You
should discuss these with the study doctor. There are some side effects that cannot be
predicted. These side effects are unlikely to happen.
Temporary increase in the blood sugar level (hyperglycemia), a condition that is
generally easily treated with no long-term consequences if monitored and treated
appropriately
Inflammation of the lung (pneumonitis) caused by the sugar-rich solution injected,
which is a serious but rare complication
Pain
Infection
All the information collected during the research project will remain strictly confidential to
the extent provided by law although confidentiality cannot be guaranteed as there is a risk
of breach of privacy.
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Should you become injured or ill as a result of participating in the study, all medical care
will be provided to you at no cost.
Confidentiality:
The study investigators are committed to respecting your privacy. Any documents
containing identifiable information will be stored in a locked cabinet at Victoria Hospital,
accessible only to the research team. A unique study number will be assigned to your
data. A list linking your study number with your initials and hospital identification number
will stored on a password-protected computer on a secure network behind institutional
firewalls at Victoria Hospital. All documentation will be destroyed 15 years after the
ata retention policy. De-identified data will be
entered in an institutional database protected by a firewall.
Qualified representatives of the following organizations may look at your medical/clinical
study records at the site where these records are held, for quality assurance (to check
that the information collected for the study is correct and follows proper laws and
guidelines).
Representatives of Lawson Quality Assurance Education Program
Representatives of the University of Western Ontario Health Sciences Research
Ethics Board that oversees the ethical conduct of this study
Compensation and Costs:
You will not be reimbursed for your participation in this study. There is no compensation
to you in relation to this research study.
Rights as a Participant:
You do not waive any legal right by signing this consent form.
If you have any questions about your rights as a research participant or the conduct of
this study, you may contact the Patient Experience Office at LHSC at
or access the online form at:

Questions about the Study:
If you have questions about the study contact the principal investigator, Dr. Richard
Malthaner at
or Deb Lewis, study coordinator at
.
A copy of this letter of information & consent is for you to keep.
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Consent Form
This study has been explained to me and any questions I had have been answered. I
know that I may leave the study at any time. I agree to participate in the study.

____________________
Print Name of Participant

___________________
Signature of Participant

__________________
Date

My signature means that I have explained the study to the participant named above. I
have answered all questions.
____________________
Print Name of Person
Obtaining Consent

___________________
Signature

Was the participant assisted during the consent process?

__________________
Date

YES

NO

If YES, please check the relevant box and complete the signature space below:
The person signing below acted as a translator for the participant during the consent
process and attests that the study as set out in this form was accurately translated and
has had any questions answered.

_____________________
Print Name of Translator

___________________
Signature

__________________
Date

_____________________
Language
The consent form was read to the participant. The person signing below attests that the
study as set out in this form was accurately explained to, and has had any questions
answered.
_____________________
Print Name of Witness

___________________
Signature

_____________________
Relationship to Participant
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__________________
Date

Appendix H

Appendix I

Appendix J

This is Patient #1 from Figure 5-A. Red line denotes when D50 was administered (43
hours here). There are various points recorded with time in hours in the X-axis, and air
leak rate in mL/min in the Y-axis. The area under the curve represents the volume of air.
We can calculate this area under the curve by using the trapezoidal rule. The area of
interest is chosen, here it is between the last recorded value before the red line (41
hours) up since the 17 hours mark, so the volume of the preceding 24 hours is
calculated. In this situation, there is no recorded flow at 17 hours, but the air leak rate at
16 and 19 hours are known. It is therefore possible to approximate the air flow rate at 17
hours.

The area under the curve is segmented in several trapezia. Each trapezius surface area
(TSA) is calculated using the formula TSA = h(a + b)/2. The sum of each trapezius
surface area provides the volume of air leaked in that time frame.

b

a

h

Appendix K
(edited to remove surgeon and dates)

Appendix L
Example of RStudio code used to create the segmented regressions/interrupted time
series (p-value associated with the immediate impact of D50 is circled in red)
Patient #6:

Patient #7

Appendix M
The terms (Glucose OR dextrose OR Glucose Solution, Hypertonic) AND (Pleurodesis
OR pneumothorax OR pneumothoraces) were used on PubMed, Google Scholar and
SCOPUS. Cochrane database was searched for the term

There was
no restriction on publication date range. Mr. David Le Sauvage, librarian at Western
University, assisted with this search strategy. Two authors (M Qiabi, A Ednie) worked
independently and screened available studies. The references of all relevant studies
were manually assessed to avoid missing any available paper.
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